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 Nucleolar Essential Protein 1 (Nep1) is required for small subunit (SSU) 
ribosomal RNA (rRNA) maturation and is mutated in Bowen–Conradi Syndrome. 
Although yeast (Saccharomyces cerevisiae) Nep1 interacts with a consensus 
sequence found in three regions of the SSU rRNA, the molecular details of the 
interaction are unknown. Nep1 is a SPOUT RNA methyltransferase, and can catalyze 
methylation at the N1 position of pseudouridine. Nep1 is also involved in assembly of 
Rps19, an SSU ribosomal protein, into the SSU. Mutations in Nep1 that result in 
decreased methyl donor binding do not result in lethality, suggesting that enzymatic 
activity may not be required for function, and RNA binding may play a more 
important role. To study these interactions, the crystal structures of the ScNep1 dimer 
and its complexes with RNA were determined. The results demonstrate that Nep1 
recognizes its RNA site via base-specific interactions and stabilizes a stem-loop in the 
bound RNA. Furthermore, the observed RNA structure contradicts the structures of 
the Nep1-binding sites within mature rRNA, suggesting that the Nep1 changes rRNA 
structure upon binding. Finally, a uridine base is bound in the active site of Nep1, 
positioned for a methyltransfer at the C5 position, supporting Nep1's role as an N1-
specific pseudouridine methyltransferase. 
In addition to the work completed with the Nep1 project, structural 
characterization of Rio3 Kinase is reported, as well as collaborative work in the 
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Chapter 1: Introduction 
1.1: Overview 
Biochemistry is known as the chemistry of life. It is the study of structure-
function relationships to determine cellular processes. Primary DNA sequences are 
transcribed into RNA, and then later translated into amino acids by the ribosome.  
The twenty possible natural amino acids are connected linearly by a peptide bond, 
forming what is known as a polypeptide chain. These polypeptide chains then take on 
a secondary structure, specifically determined by the sequence of amino acids in the 
chain, leading to the formation of alpha helices and beta sheets. The final proteins 
products are globular arrangements of secondary structure (also known as tertiary 
structure) stabilized into a low energy state.  Once folded correctly into proper three-
dimensional globular structures, proteins are tasked to carry out varied cellular 
processes essential to life of all organisms. 
At the core of protein biochemistry is the synthesis of the polypeptide chain.  
A ribonucleoprotein complex called the ribosome performs this process via a 
mechanism known as translation; this process translates the genetic code into amino 
acids leading to the synthesis of a fully functional protein. The eukaryotic ribosome 
is made up of ribosomal RNA (rRNA) and ribosomal proteins assembled into two 
mature subunits, one larger than the other. The large subunit (60S) and small subunit 
(40S) come together independently during translation to form the complete 80S 
ribosome. It takes a highly ordered, well-regulated scheme for the cell to 
manufacture rRNA and process it into its mature fragments. In eukaryotes, the initial 
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35S pre-rRNA (part of the 90S pre-ribosome) is chopped into smaller pieces through 
a series of cleavages (1-3). The final mature rRNA products are the 5.8S, 25S and 
the 18S (Fig. 1.1). There are estimated to be over 170 proteins that are involved in 
the maturation of the eukaryotic ribosome (3). These proteins carry out multiple 
different functions toward the final goal of producing a fully functional mature 80S 
ribosome, including direction of cleavage steps, rRNA modifications (such as 
methylation and pseudouridylation), transport, and chaperone function (3-9). The 
structural characterization of known ribosomal processing factors with unknown 
functions can provide a molecular analysis into their role in ribosome biogenesis. 
Currently, the only two ways to acquire molecular resolution better than 4.0 Å 
of protein structure is by x-ray crystallography or nuclear magnetic resonance 
(NMR).  In the late 1950’s, myoglobin was the first protein for which a crystal 
structure was solved, credited to John Kendrew with a Nobel Prize in 1962 (10).  
Including the contribution from NMR, which saw its first protein structure in 1984 
by Kurt Wüthrich, there are greater than 65,675 protein structures deposited to the 
protein database (11, 12). Amazingly, just five short years ago, there were fewer than 
38,000 submitted structures (12). X-ray crystallography methods have advanced so 
quickly the past half-decade that it is an arduous task to keep up with new 
technology.  The widespread availability/affordability of high-throughput machinery, 
in house diffraction systems, and improved/new crystallographic software 
(Phenix/COOT/CCP4) are major factors for this recent success.  Even with all the 
recent success, x-ray crystallography historically and currently has the same rate-
limiting step, and that is the growth of suitable crystals that yield high-resolution 
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diffraction patterns.  This manuscript will describe multiple projects, both successful 
and challenging, and will provide a glimpse into the exciting trials of x-ray 
crystallography. 
1.2: Background: Nep1 
Nucleolar essential protein 1 (Nep1) is a highly conserved protein required for 
ribosome biogenesis and found in organisms from archaea to humans. Nep1 was first 
identified in fission yeast (Schizosaccharomyces pombe) as a high-copy number 
suppressor of a mating deficiency caused by a mutation in the effector domain of 
Ras1 and thus named Mra1 (multicopy suppressor of Ras 1) (13). In yeast, Nep1 has 
also been designated as Emg1, for essential for mitotic growth 1 (14).  Emg1 is 
required for 18S SSU rRNA maturation (14, 15). To release the yeast 18S SSU 
rRNA from the pre-rRNA, cleavage must occur at four sites, designated sites A0, 
A1, A2 and D (2, 3). Cleavage at site A0 and A1 truncates the 5’-end of the rRNA 
transcript, while cleavage at A2 results in separation of a 20S pre-rRNA species from 
the 5.8S and 25S. Final cleavage at site D produces the mature 18S SSU rRNA (Fig. 
1.1). Depletion of Emg1 results in loss of cleavage at site A2, which results in an 
accumulation of a 21S SSU rRNA species (15). This is a result of cleavage at site 
A3, which normally happens after site A2 cleavage in the maturation of the 5’-end of 
the 5.8S rRNA species (2). 
1.3: Introduction to the SPOUT Family 
Recently in 2008, work published by Taylor et al. and Leulliot et al., provided 
the first looks at Nep1/Emg1 with a dimeric structure from archaebacterium 
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Methanocaldococcus jannaschii and a monomeric structure from Saccharomyces 
cerevisiae (16, 17). Structural analysis of archaeal Nep1, of our own then unpublished 
work and the work by Taylor et al, revealed structural homology to the SPOUT 
family of RNA methyltransferases.  The name SPOUT is derived from the family’s 
original methyltransferase members, SpoU and TrmD (18). The family is now much 
larger, but they all still have shared structural characteristics (16, 18, 19). The 
members of the family each contain a SPOUT methyltransferase domain and may 
contain additional inserted domains required for selectivity of RNA substrates. 
Members of the SPOUT family all contain a signature methyltransferase knotted fold, 
where S-adenosylmethionine (SAM) is the source for the methyl group used in the 
methyl transfer. Thus far, SPOUT methyltransferases have been implicated in the 
methylation of ribose 2’-OH (2’-O-ribose), guanine N1 (m1G), uridine C3 (m3U) and 
N3 of pseudouridine (m3ψ) (19, 20). Within the family, Nep1 proteins are most 
closely related to the TrmD and RsmE subfamilies, which catalyze m1G and m3U 
modifications, respectively (19). All SPOUT methyltransferases characterized thus 
far are dimeric, as is Nep1. 
1.4: Nep1 is a Pseudouridine RNA Methyltransferase 
RNA-binding screens have indicated that Nep1 binds to the consensus 
sequence C/UUCAAC (21). This sequence is found in three regions of 18S rRNA in 
yeast including the stem loop of helix 31, bases 1189-1193, and part of the stem of 
helix 42, bases 1565–1570 (Fig. 1.2). In the RNA three-hybrid screen that identified 
this consensus sequence, all the binding sites were located in the unpaired region of a 
stem loop structure predicted by RNA secondary structure predictions (21). 
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Recent work has identified Nep1 as a pseudouridine N1-methyltransferase 
(22) (Fig. 1.3). Wurm et al. showed that both human and M. jannaschii Nep1 are 
capable of catalyzing methylation on pseudouridine-containing RNA sequences, 
especially C/UψCAAC. This sequence is the Nep1 site found in the stem loop of 
helix 31 of yeast 18S rRNA mentioned above (22). This pseuoduridine, located at 
position 1189, is hypermodified in yeast, with a 3-amino-3-carboxypropyl group on 
the N3 position and a methyl group on the N1 position (m1acp3ψ) (23). Nep1 is the 
first identified example of an N1-specific pseudouridine methyltransferase (22).    
1.5: Nep1 Interactions with Rps19 and SnR57 
Nep1 plays an unclear role in the loading of Rps19 into the SSU. Rps19 is a 
small ribosomal subunit (SSU) ribosomal protein found only in archaeal and 
eukaryotic ribosomes and is also known as a protein mutated in roughly 25% of cases 
of Diamond–Blackfan Anemia, a rare congenital disease characterized by defects in 
red blood cell development and predisposition to cancers (24, 25). Rps19 is an 
essential protein, and its depletion also results in the loss of cleavage at site A2 (16, 
25-28). In yeast, studies performed by Buchhaupt et al., overexpression of Rps19 was 
shown to partially suppress the phenotype observed with loss of Nep1 function. 
Surprisingly, this suppression is enhanced by deleting snr57, the C/D box snoRNA 
that guides 2’-O-ribose methylation at 18S G1572 (21, 29). In fact, deletion of Nep1 
is not lethal in an snR57 deletion mutant (21). Taken together, it appears that Nep1 
aids in Rps19 loading and is essential in the presence of snr57. This function is either 
through direct interaction with Rps19, or alteration of the rRNA structure (21). Since 
the defects in rRNA processing observed in Nep1 and Rps19 depletion are identical, 
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it is likely that some of the ribosome biogenesis defect caused by loss of Nep1 is a 
consequence of improper Rps19 assembly. 
As mentioned above and shown in Figure 1.2, Nep1 consensus binding 
sequence C/UUCAAC is found in helix 31 (1188-1193 and helix 42 (1565-1570). 
Both these binding sites are near helix 41, where Rps19 was shown to bind using cryo 
electron microscopy (cryo-EM) reconstructions (21, 30). In addition, one of the sites, 
between bases 1565 and 1570, overlaps with the predicted binding site of snR57 
(bases 1569–1583). 
1.6: Nep1 Objectives 
The initial focus of my research was to determine the first structure of Nep1 
and use structural analysis to understand its role in ribosome biogenesis. When, as 
mentioned, Taylor et al. reported the first Nep1 structure in 2008 (16) my research 
took on a new direction.  Utilizing the Nep1 structure, we asked the following 
questions: 
1. Is it possible to crystallize and solve the structure of Nep1 in complex with 
cognate target RNA,  
2. If so, what drives specificity for the target RNA, and what is a plausible 
mechanism for RNA methylation. 
3. What is the functional role of Nep1 in ribosome biogenesis? 
To address these questions, in chapter 2 I will describe the purification and 
initial crystallization and structure solution of Archaeaglobis fulgidus Nep1 (AfNep1) 
as well as the structure of Saccharomyces cerevisiae Nep1/Emg1 (ScNep1) solved via 
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seleno-methionine substitution and molecular replacement, respectively. Chapter 2 
will also describe the methods utilized, including RNA oligonucleotide design, to 
acquire two x-ray structures of a complex formed between ScNep1 and a 14 base 
cognate RNA oligonucleotide. Chapters 3 and 4 will introduce all four structures 
determined from the experiments detailed in chapter 2 and provide structural analysis 
highlighting the active site, dimer interface and interactions with bound RNA. 
Conclusions to the Nep1 project will be presented in chapter 5. 
1.7: Rio3 Background 
Kinases are involved in a wide range of cellular processes including and not 
limited to cell cycle regulation, DNA replication, transcription, and ribosome 
biogenesis (31, 32).  Atypical protein kinases are defined as members of the kinase 
superfamily that possess phosphoryl transfer activity without significant sequence 
homology to canonical eukaryotic protein kinases (ePK). The RIO kinase family is 
classified within this group of atypical kinases because of the very low sequence 
homology to ePKs and the ability to phosphorylate serine residues (33, 34).  
Structural studies of Rio1 and Rio2 show the RIO domain is structurally similar to 
ePK’s kinase domain (35-37).  The founding member of the RIO family (Rio1) has 
been shown along with Rio2 to be essential in ribosome biogenesis, more 
specifically the maturation of the 20S to the fully mature 18S ribosome (38-41).  
There are over 500 serine/threonine/tyrosine kinases in the human genome 
(42).  Of those kinases, there are 13 families of atypical kinases, which represent 40 
of the 500+ kinases (42).  The functional subdomains of the 250-300 amino acid 
kinase domain are structurally conserved among the canonical eukaryotic protein 
 
8 
kinases (43). These subdomains include: nucleotide binding loop, known as the P-
loop; hinge region, which interacts with the adenine of adenosine triphosphate; 
“catalytic loop” containing catalytic residues asparagine and aspartate; activation 
loop or APE; metal binding loop; and peptide binding sub-domains on the C-
terminus (39, 43-45). Structural studies of archaeal Rio1 and Rio2 have shown the 
absence of the activation loop sub-domain and C-terminal peptide binding sub-
domains (35, 37).  
All metazoa carry the gene for the third member of the RIO kinase family.  
Rio3 is conserved in all multi-cellular eukaryotes. However, Rio3 is not present in 
yeast and archaea, unlike Rio1 and Rio2.  Even though Rio1 and Rio2 share 
conservation through archaea and yeast, Rio3 and Rio1 are more closely related. 
With an overall sequence alignment (ClustalW) identity of 45% for the RIO kinase 
domain alone, Rio3 human (RioK3) and Rio1 human (RioK1) are highly 
homologous and come from the same phylogeny (Fig. 1.4A) (46, 47). Rio2 human 
(RioK2) and RioK3 are less related, with an overall alignment identity for the RIO 
domain identity of just 19%. Each member has a unique N-terminal and C-terminal 
domain/sub-domain. Rio2’s conserved N-terminal winged helix turn helix (wHTH) 
domain is known via archaeal Rio2 structures. However, eukaryotic Rio1 has an 
extended N-terminal domain of unknown structure not present in archaea. Rio3 
contains a longer unknown domain (in comparison to Rio1) on the N-terminus, 
consisting of ~200 amino acids (48).  Figure 1.4B shows the domain arrangement for 
the three members of the RIO family.  
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 Recently, RioK3 has been identified as an oncogene in pancreatic ductal 
adenocarcinoma and was shown to significantly alter cytoskeletal architecture when 
overexpressed (49). The characteristic phenotype is the formation of lamellipodia, an 
appendage like protrusion commonly seen in migrating and invasive cells (50). 
Overexpression of RioK3 was also shown to promote this invasive cell phenotype by 
the activation of a small GTPase known as Rac (49). It is still uncertain as to how 
RioK3 activates Rac and whether RioK3 requires kinase function, either through 
autophosphorylation or through phosphorylation of a currently unknown substrate. 
The significant uncertainties of RioK3 combined with its characterization as an 
oncogene make RioK3 a prime target for further structural and biochemical studies.  
1.8: Rio3 Studies 
A major portion of my tenure at the University of Maryland has been working 
on the purification and crystallization of Rio3.  There have been successes in 
purification protocols that will be detailed in chapter 6.   For every success in the 
Rio3 project, there has been an equal roadblock at protein stability, initial crystal 
screening, as well as in the optimization of diffraction from acquired crystals. Chapter 
7 will provide details to the exhaustive approach to improve crystal quality and 
diffraction. Despite my inability to produce suitable crystals prior to the end of my 
time here, the work described will lay the foundation for future success in the 
structural and biochemical characterization of Rio3. 
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1.9: Additional Studies 
In addition to the previously described work, I have participated in a variety of 
collaborative projects. Chapter 8 will describe work performed with Dr. David 
Fushman, a co-member of the Center for Biomolecular Structure and Organization, 
which focused on Ubiquitin and Ubiquitin in complex with E2-25K. Finally, chapter 
9 contains the published work I completed in collaboration with then senior graduate 
student Dr. Patrick McTamney and his advisor, Dr Steven Rokita, at the University of 
Maryland.  The collaborations were exciting and provided experiences that guided me 






Figure 1.1: 35S Pre-rRNA Processing  
Thin arrows indicate specific cleavage sites. Cleavage at A0 and A1 occur first off the 
5’-end. Next, cleavage at site A2 results in the separation of the 20S pre-rRNA, which 
later becomes the final mature 18S rRNA.  Depletion of Nep1 (loss of cleavage at site 
A2) results in accumulation of the 21S pre-rRNA portion depicted in green, caused by 









Figure 1.2: 18S RNA Sequence and Structure  
Based on the secondary structure prediction for S. cerevisiae 18S rRNA from the 
Comparative RNA Web Site (www.rna.ccbb.utexas.edu).  Selected regions of 
secondary structure are colored orange, cyan and green for helix 31, 41 and 42 
respectively. Red color indicates Nep1 consensus sites. The snR57-binding site is 
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highlighted in yellow. Purple denotes parts of rRNA within 4 Å of S19 (shown as 
blue cartoon). Asterisk indicates the site of interaction between helix 41 and 42. 







Figure 1.3: Nep1 Catalyzed Reaction  
Nep1 catalyzes the transfer of the methyl group (circled in red) from S-adenosyl 
methionine (SAM) to the N1 position of pseudouridine (ψ) resulting in N1-methyl 




Figure 1.4: Eukaryotic Rio Family Cladogram and Domain Arrangement 
A) Cladogram showing evolutionary relationships (47). PKA (c-AMP dependent 
protein kinase A) represents canonical eukaryotic kinase. B) Rio family members 
include a conserved atypical Rio kinase domain, with Rio1 and Rio3 being more 
similar (light grey used for Rio1 and Rio3 to show similarity vs dark grey for Rio2).  
Each family member has a unique N-terminal domain (Rio1 and Rio3 both unknown 




Chapter 2: Purification and Crystallography of AfNep1 and ScNep1 
2.1: Purification Protocol for AfNep1 and ScNep1 
Archaeoglobis fulgidus was originally discovered in 1987 deep in an Italian 
thermal vent (52, 53). This hyperthermophilic organism was later discovered to 
optimally thrive at 76°C (54). In order to survive, A. fulgidus has evolved to prevent 
the denaturing of proteins at high temperatures.  The elevated thermal stability of A. 
fulgidus proteins allows the design of a purification protocol for their expression in E. 
coli that utilizes wide differences in thermal denaturation properties. 
  The full-length Nep1 gene was PCR amplified from A. fulgidus and S. 
cerevisiae genomic DNA (ATCC) and subcloned into a plasmid vector (pDest527) 
containing an N-terminal 6X histidine tag followed by a Tobacco Etch Virus (TEV) 
protease cleavage site (plasmids obtained from Protein Expression Laboratory, SAIC, 
Frederick, MD) (55). These constructs were transformed into E. coli Rosetta™-DE3-
pLysS cells (Novagen). Expression cultures were grown in LB media at 37 ºC and 
induced with 1 mM isopropyl-beta-D-thiogalactopyranoside (IPTG) at OD600 of 0.6 
for 4 hours for AfNep1. For ScNep1, cultures were grown at 37°C until OD600 of 
0.6, then cooled to 20°C and induced with 1 mM IPTG for overnight expression. 
After expression, the cells were harvested by centrifugation. For AfNep1, cells were 
resuspended in 50 mL of 50 mM Tris pH 8.0, 300 mM NaCl, 0.2 % β-
mercaptoethanol, 0.2 X Bugbuster™ (Novagen) and 0.1 mg/ml DNase1 (Roche) per 
liter of expression culture and stirred at room temperature. After 30 minutes, the 
lysate was transferred to centrifuge tubes and placed in a 75 °C water bath for 15 
minutes to denature the E. coli proteins and then immediately centrifuged for 20 
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minutes at 18000 rpm (rotor: Beckman 45 Ti) in an ultracentrifuge to remove 
insoluble/denatured material. For ScNep1, cells were resuspended in 50 mL of 25 
mM Tris pH 8.0, 200 mM NaCl, 0.2% β-mercaptoethanol, 0.2 X Bugbuster™ and 0.1 
mg/ml DNase1 (Roche) per liter of expression culture and stirred at 4°C. After 45 
minutes, the lysate was transferred to centrifuge tubes and centrifuged for 20 minutes 
at 18000 rpm (45 Ti). The supernatants were passed through a 0.22 µM filter and 
loaded onto a 5 ml HisTrap HP column (GE Healthcare) equilibrated in buffer 
containing 50 mM Tris pH 8.0, 300 mM NaCl and 0.2 % β-mercaptoethanol for Nep1 
and 25 mM Tris pH 8.0, 200 mM NaCl and 0.2% β-mercaptoethanol for ScNep1. The 
bound AfNep1/ScNep1 was washed with 100 mM imidazole in the respective 
equilibration buffer and then eluted with a gradient from 100 mM to 1 M imidazole in 
equilibration buffer in 20 column volumes. The fractions containing AfNep1/ScNep1 
were pooled and dialysed overnight into 25 mM Tris pH 8.0, 300 mM NaCl, 1 mM 
EDTA and 0.2 % β-mercaptoethanol for AfNep1 and 25 mM Tris pH 8.0, 200 mM 
NaCl, 1mM EDTA and 0.2 % β-mercaptoethanol for ScNep1. In the case of AfNep1, 
attempts made to remove the tags by TEV protease cleavage were unsuccessful. The 
tag was cleaved in ScNep1. The resulting protein contained a single extra glycine 
residue at the N-terminus. The cleaved ScNep1 protein was passed over a 5 ml 
HisTrap HP column (GE Healthcare) a second time to remove uncleaved protein and 
TEV protease (55). The proteins were concentrated to 5 - 10 mg/ml and further 
purified to >99% by size exclusion chromatography using a Superdex 75™ column 
(GE Healthcare) equilibrated in 20 mM Tris pH 8.0, 300 mM NaCl, 1 mM EDTA and 
0.2% β-mercaptoethanol for Nep1, and a Superdex 200™ column (GE Healthcare) 
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equilibrated in 20 mM Tris pH 8.0, 200 mM NaCl, 1 mM EDTA and 0.2% β-
mercaptoethanol for ScNep1. The protein was concentrated again to 8 mg/ml for 
AfNep1 and 20 mg/ml for ScNep1. This preparation was stored at 4°C until 
crystallization screening. Se-Met AfNep1 was expressed in minimal media with all 
amino acids supplemented except for methionine, which was replaced by seleno-
methionine (Se-Met). Reducing agent (0.2% β-mercaptoethanol) was added to Se-
Met protein immediately prior to crystallization screening. 
2.2: Crystallography 
2.2A: RNA Oligonucleotide Design 
Table 2.1 shows the RNA oligonucleotides of varying lengths and sequences 
purchased HPLC-purified from IDT.  At the time of oligonucleotide design, the only 
information available was the identification of the ScNep1 consensus binding site, 
C/UUCAAC, and RNA secondary structure prediction of the target sequence (21, 51). 
It was not known that pseudouridine was required for methylation by ScNep1. The 
initial design utilized different lengths of the identified sequence (oligo #1, #3 and #4) 
and extending the consensus sequence with Watson-Crick G-C base pairs to stabilize 
the predicted stem-loop secondary structure (oligo #2). 
ScNep1 was mixed at a 1:1 molar ratio with the RNA oligonucleotides 
resuspended in 10 mM Tris pH 8.0. The mixtures were analyzed by gel 
electrophoresis on a 6% TBE-polyacrylamide gel and visualized by UV after 
ethidium bromide staining to determine stoichiometric complex formation.  The 14-
base RNA oligo #2 containing the sequence 5’-GGGCUUCAACGCCC-3’ was the 
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best at producing stoichiometric complexes. Oligo #3 containing 5’-
CUCUUCAACGAG-3’ also showed good complex formation, however no crystals 
were obtained with RNA present in the active site. 
2.2B: Crystallization Conditions 
Initial crystallization conditions were obtained through utilization of several 
sparse matrix screens (Qiagen, Emerald Biosystems Inc., Nextal, Hampton Research) 
with the sitting drop vapor diffusion method. Crystals of the AfNep1 protein were 
obtained from drops containing 3-4 M sodium chloride, 100 mM HEPES buffer pH 
7.0 – 8.0 placed over 1 mL reservoirs. Crystals of free ScNep1 were obtained from 
several conditions, including 50 mM BIS-TRIS, pH 6.5, 50 mM ammonium sulfate, 
30% pentaerythritol ethoxylate (15/4 EO/OH) and 20% glycerol, used for data 
collection. The ScNep1/1RNA complex crystallized in 100 mM HEPES, pH7.0 and 
10% PEG (polyethylene glycol) 6000 and crystals of the ScNep1/2RNA complex 
were obtained in 50 mM MES, pH 6.0, 15 mM magnesium sulfate and 7% PEG 4000. 
Diffraction quality crystals were obtained after 4-6 days at 20 °C. (Fig. 2.1) 
2.2C: Data Collection 
Crystals were flash frozen in mother liquor supplemented with 20% glycerol 
for all crystals. Cryogenic conditions are used to protect crystals from radiation 
damage during data collection as well as to prevent icing during cryo-preservation. 
Diffraction data for the native and Se-Met were collected at 100 K at the NECAT 
beamline at the Advanced Photon Source (APS), Argonne, Illinois. Data from the Se-
Met crystals were collected at one wavelength (peak). All data were integrated with 
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DENZO and merged with Scalepack within HKL2000 (56). Tables 2.2-2.6 show 
condensed Scalepack output log files for all four structures, including the Se-Met log 
file from data used for phasing (Table 2.2). Split into shells of resolution, the log files 
are used as a tool to understand the quality of the data after being integrated and 
merged. Specifically, the log files presented in Tables 2.2-2.6 show redundancy and 
completeness of the shells, and also provide data quality statistics.  Understanding 
these output files is crucial in determining not only inborn problems in the diffraction 
quality resulting from poor crystals, but also the quality of the choices made during 
the integration and merging process.     
2.2D: Structure Determination 
X-rays behave as both a particle and a wave.  The ability to “transform” 
diffraction from the x-ray beam after hitting a protein crystal into an electron density 
map via the electron density equation (Eq. 1) can only be accomplished when three 
variables are known. 
                  
                
Equation 1: Electron Density (ρ) Equation. Red represents the structure factor 
amplitude. Green represents the indices, hkl, of the unit cell (position). Blue 
represents the phase term of the electromagnetic wave. V is the unit cell volume. 
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The three terms shown in color in Equation 1 represent the location of the diffraction 
spots (known as the hkl’s or indices colored in green) in reciprocal space, intensity of 
the diffraction (known as amplitude colored in red), and finally the phase (ϕ) of the 
wave colored in blue. A two-dimensional detector can only acquire measurements for 
position and amplitude. The inability for the detector to simultaneously measure the 
phase of the wave is known as the “phase problem”.   
In order to acquire a three dimensional structure from a two dimensional 
detector a method for acquiring phases must be addressed. The availability of 
adjustable wavelengths at synchrotrons has provided a great method for acquiring 
phases through single wavelength anomalous diffraction (SAD) (57, 58). Phasing via 
SAD methods requires the presence of anomalously diffracting atoms in the structure. 
This can sometimes be accomplished using the native sulfur atoms (as you will see in 
chapter 9). However, this is generally more challenging and requires very high 
resolution (2.0 Å or less) and clean diffraction patterns, including a robust crystal that 
withstands radiation damage (59). Heavy atoms can also be introduced artificially, 
either through replacement during expression or by heavy atom soaking (60, 61).  The 
most common method of heavy atom incorporation is achieved with replacement of 
methionine residues with selenomethionine (Se-Met). This replacement should not 
cause any changes to the crystal form (space group and unit cell), and therefore 
should be “isomorphic” to the native crystal.  The Patterson function is used to take 
advantage of the heavy atom’s absorption edge and anomalous diffraction associated 
with collecting data at that particular wavelength and determines the location of the 
introduced heavy atoms.  Once the locations are determined, phases for the heavy 
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atom substructure can be determined and the first electron density map can be 
viewed.  From this point, there are many options for model building. 
Another option for phasing is called molecular replacement and is now the 
most common method of phasing (~75%) (12). Molecular replacement is more of a 
brute force method that rotates and translates a known homologous model (>20% 
identity) looking for a similar match to the unknown model. Modern search programs, 
such as Phaser and MOLREP, perform this search by independent rotational and 
translational searches.  First, a proper rotational orientation for the search model is 
determined in the asymmetric unit by aligning the Patterson maps for the search 
model with the experimental data.  After the correct rotational orientation is 
determined, the search model undergoes translational movements to better align the 
Patterson maps. If the resolution is high enough and with today’s impressive 
processing power in computers, in a relatively short time, initial phases can be 
determined by this rotation and translation search method.  Once the phases are 
refined, an electron density map can be viewed.    
The AfNep1 structure was solved using single wavelength anomalous 
diffraction (SAD) data with the Se-Met protein crystals, collected to 2.0 Å. The 
AutoSharp program suite was used to obtain the phases using the SAD method, apply 
solvent flattening and density modification to the initial electron density map, and 
perform automatic model building with wARP (62, 63). The complete model was 
finalized by rebuilding in COOT and refinement with REFMAC5 (64, 65). The model 
was then used to phase the native data set using MOLREP as part of CCP4i program 
suite (66-69). The ScNep1 structures were solved by molecular replacement in 
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MOLREP or Phaser using PDB ID 2V3J (17, 70). All models were subjected to 
several rounds of building in COOT and refinement using REFMAC5 or PHENIX 
(64, 65, 71, 72). Translation libration screw-motion (TLS) groups were determined 
using the TLSMD server (73). Refinement statistics are provided in Table 2.7.  The 
coordinates and structure factors have been deposited in the Protein Data Bank 
(accession codes 3O7B for AfNep1, 3OII, 3OIJ and 3OIN for ScNep1 free dimer, 






Figure 2.1: AfNep1 and ScNep1 Crystals  
A) AfNep1 crystals containing Se-Met, (B) ScNep1, (C) ScNep1 with one molecule 
of RNA and (D) ScNep1 with two molecules of RNA. 
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Table 2.1: RNA Oligonucleotides  
Green represents consensus yeast consensus sequence (21). Red coloring indicates 
mutations from native yeast 18S RNA. 
 
• Oligo 1 - 14 base native yeast 
  5’-GCU CUU CAA CGA GG-3’ 
• Oligo 2  - mutated yeast  *crystallized with Emg1* 
  5’-GGG CUU CAA CGC CC-3’ 
• Oligo 3 – 12 base native yeast 
  5’-CUC UUC AAC GAG-3’ 
• Oligo 4 – 8 base native yeast 
























Chapter 3: Description of AfNep1 and ScNep1 in the Free State 
3.1: Overview 
Structural analysis of AfNep1 and ScNep1 supported previously reported 
structures that Nep1 does indeed belong to the SPOUT family of methyltransferases 
and contained all of the characteristic family traits, including the knotted 
methyltransferase fold (16, 17). This chapter will present a structural overview of 
Nep1, highlighting Nep1’s relationship to the SPOUT family of methyltransferases. 
Secondly,  all SPOUT family proteins have been shown to be dimers (19), as Nep1 is 
not an exception, a description of the dimer interface combined with comparisons 
between AfNep1 and ScNep1 will be  presented in detail. Research on the 
characterization of the Nep1 dimer interface was progressing very quickly and was 
near write up and submission, however, the competition was fierce and the direction 
of the project had to adapt (Chapter 4) after other laboratories released initial 
structural descriptions and also supported the presence of an obligate dimer (16, 17). 
3.2: Basic Structural Description 
The overall structure of the Nep1 protein, shown in Figure 3.1, consists of a 
central β-sheet surrounded by α-helices on either side, characteristic of a Rossmann 
fold (16, 17). The central β-sheet is comprised of six β-strands, five of which are 
parallel to each other and one anti-parallel (β3), with an additional two loosely 
ordered strands completing the sheet (β4, β5). The order in which sequential β-
strands form the β-sheet is β5-β4-β3-β2-β1-β7-β6-β8. The helices within the 
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Rossmann domain are located between β1 and β2 (αA, αAb, αd´), β3 and β4 (αc, 
Hc) and after β8 (αE). Two additional helices, Hb´ and αa´ are present in a small 
Nep1 specific 40 amino-acid insertion between β1 and α2 (residues 48–88). This 
insertion and the orientation of αa´ is characteristic of Nep1 SPOUT 
methyltransferases, and also exhibits the most difference between the archaeal and 
yeast structures. This domain is moderately conserved based on sequence 
comparison with eukaryotic Nep1 sequences (Fig. 3.1). Electron density was 
observed for all the residues except 1–27 for both monomers, 56–64 for monomer A 
and 54–65 and 153–157 for monomer B, of ScNep1, and for all but the last three for 
AfNep1. In both models, density was observed in the SAM-binding pocket into 
which SAH was modeled. 
3.3: Dimer Formation 
Although the structure of Nep1 from yeast has been previously reported, the 
deposited structure (PDB ID 2V3J) was monomeric (17). In the crystal structure of 
ScNep1 bound to SAH presented here, the molecule is dimeric. In both archaea and 
yeast, a large interacting surface is observed between Nep1 molecules that buries 
surface area in excess of 845 Å2 for AfNep1 and around 1475 Å2 for ScNep1. The 
dimer interface is formed primarily between residues on helices αA and αE and the 
N-terminal end of αc'. The interactions form in a 2-fold symmetric interface that can 
be seen in Figure 3.2A and Figure 3.2B (Fig. 3.3 for AfNep1). The residues at the 
dimer interface of ScNep1 are highly conserved among eukaryotes, but less so 
among archaeal organisms (Figs. 3.4 and 3.5). The ScNep1 interface consists of a 
mixture of electrostatic interactions and hydrogen bonds on the edges and a few 
 
34 
hydrophobic interactions at the center, and several water molecules were observed in 
the charged regions of the interface. This shows a less tight dimer interface than that 
observed for the AfNep1 interface, which contains a stabilizing disulfide bond, 
commonly used to stabilize protein structure in thermophiles (Fig. 3.3) (74). 
Interestingly, in ScNep1, the side chain of the C-terminal Leu 252 forms 
hydrophobic packing interactions at the interface and the carboxyl group at the end 
of the chain forms a hydrogen bond with the side chain of Ser 228 and Asn 229 and 
the backbone amide nitrogen of Asn 229 of the other monomer (Fig. 3.2B and 3.2C). 
Therefore, the C-terminus participates in dimer formation. In the previously reported 
structure of ScNep1, the construct used contained a C-terminal histidine tag that may 
have disrupted this interaction and weakened the dimer to some extent, resulting in 
monomers in the crystals (17). 
3.4: Chapter Summary 
The conserved dimer interface between the monomers of both AfNep1 and 
ScNep1 is seen throughout all members of the SPOUT family (19).  While we were 
working on exploring this dimer interface, other research laboratories published work 
confirming Nep1’s conserved dimer formation. The focus of research was no longer 
to determine a novel structure, but to determine Nep1’s involvement with target 18S 






Figure 3.1: Nep1 Sequence Alignment 
Sequence alignment from of Nep1 from S. cerevisiae (NEP1_YEAST), Homo sapiens 
(NEP1_HUMAN), Drosophila melanogaster (NEP1_DROME) and A. fulgidus 
(NEP1_ARCFU). Yellow, red and blue dots indicate residues involved in 
dimerization, RNA binding and SAM binding respectively. Secondary structure for 
yeast (top) and A. fulgidus (bottom) shown as open bars for α-helices and arrows for 
β-strands and numbered according to Leulliot et al. for yeast, and Taylor et al. for A. 




Figure 3.2: Overall Structure of ScNep1 and Dimer Interface 
A) Overall view of the ScNep1 dimer. RNA binding and catalytic regions of the 
molecules are colored red and dark blue respectively. The molecules of SAH are 
shown in sticks. Secondary structure elements are labeled according to Leulliot et al. 
(17). B) Front view of the dimerization interface of ScNep1. Residues are labeled 
with chain names and residue numbers. C) Top view of the interface showing the 
interaction of the C-terminus in the interface. Residues that are identical in eukaryotic 





Figure 3.3: The AfNep1 Dimer  
A) The symmetric AfNep1 dimer generated by symmetry operation of the 
asymmetric unit. Bound SAH molecules (not added to crystallization conditions) 
shown in yellow sticks. B) Close-up of dimerization interface. Cysteine involved in 







Figure 3.4: Conservation Maps on the Surface of ScNep1 
Residues are colored based on conservation in alignments with human and fruit fly 
Nep1 sequences using ClustalW (red = identical; green = highly conserved; blue = 
weakly conserved). The “front” view in A. is rotated 90° in either direction around 
the x-axis to produce the orientations in B. In C, “inside” refers to the dimerization 




Figure 3.5: Conservation Maps on the Surface of AfNep1  
A-C) Residues are colored based on conservation in alignments with eukaryotic Nep1 





Chapter 4: Nep1 in Complex with RNA 
4.1: Overview 
Our structures of ScNep1 are the first examples of a SPOUT 
methyltransferase bound to its target RNA.  Even more interesting is Nep1 is the only 
member of the SPOUT family known to date that methylates pseudouridine (22).  
Presented in this chapter is a base-by-base description of the interactions between 
ScNep1 and the 14 base RNA fragment.  Conformational changes between free 
ScNep1 versus ScNep1 bound to RNA and comparisons between ScNep1 with one 
molecule of RNA versus ScNep1 with two molecules of RNA are also presented in 
dedicated sections within this chapter.  
4.2: Interaction of ScNep1 with RNA 
Using the binding sequences for ScNep1 obtained through RNA three-hybrid 
screening by Buchhaupt et al. (21), a series of oligonucleotides were designed and 
tested for binding to ScNep1 in stoichiometric complexes. It was determined that an 
ideal complex was obtained when ScNep1 and a 14 base RNA fragment with the 
sequence G1G2G3C4U5U6C7A8A9C10G11C12C13C14 were mixed in a 2:2 
(monomer:RNA) ratio. Crystals were obtained for Nep1 bound to this 14 base RNA 
fragment in two crystal forms (Fig. 2.1). In one crystal form, a dimer of ScNep1 is 
bound to one RNA molecule (Fig. 2.1A). In the second crystal form, the dimer binds 
two separate RNA molecules (Fig. 2.1B). In both cases, the RNA forms a stem loop 
structure in which eight bases forming canonical base pairs in the stem and six bases 
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in the loop (UUCAAC) have base specific contacts with the protein. Electron density 
was not observed for residues 1-27 and 56-64 of both protein monomers in the RNA 
complexes, and residues 76-82 of monomer A of the two-RNA complex. There are no 
significant differences between the RNA molecules bound in the two complexes. In 
the comparison of the sequences of RNA found to bind Nep1 by RNA three-hybrid 
screens, all the sequences contained the consensus sequence C/UUCAAC, and the 
most tightly binding were those sequences that contained the consensus sequence 
within the loop of a predicted stem-loop (21). These six bases form the basis for 
specific recognition by the protein.  In the crystal containing the one RNA per dimer 
complex, the empty RNA-binding site is involved in four hydrogen bonds with the 
RNA backbone from a symmetry-related complex. 
In both complexes, the RNA binds on highly positively charged surfaces of 
the dimer as predicted in previous reports (16, 17). However, the protein contains 
significant positively charged surface that is not contacted by RNA in these structures 
(Fig. 4.2). This positively charged surface is conserved in AfNep1 as well. This is 
consistent with the idea that Nep1 binds to RNA on the pre-ribosome, which makes it 
likely that it will contact significantly more RNA than is observed with these minimal 
constructs. The regions that are not contacted by RNA in these structures contain 
many conserved residues as well, indicating that this surface is important for Nep1 
function (Fig. 3.3).  
ScNep1 provides several key interactions that confer the observed specificity 
for a UUCAAC sequence (Fig. 4.3, schematic in Fig. 4.4). The first base of the 
consensus sequence, U5, is contacted through base-specific contacts through bidentate 
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hydrogen bond interactions between the NH1 and NH2 of conserved Arg 136 of 
monomer A (A:Arg 136 NH1 and NH2) and the C2 carbonyl oxygen (O2) of the 
uridine base (Fig. 4.3A, 4.4). There are no contacts between the protein and C4 
carbonyl oxygen (O4), which explains the observation that a cytosine, which differs 
from uracil solely by an amine group at C4, can substitute at this position (21).  
The next uracil in the consensus sequence, U6, is the site of modification by 
the enzyme. It is flipped out from the loop and bound in a pocket between the two 
monomers, near the bound SAH molecule, in the enzyme active site (Fig. 4.3A, B). It 
is recognized by a direct hydrogen bond with A:Arg 132 NE (Nε of arginine 132 of 
monomer A)  at the U6 O2 (C2 carbonyl oxygen of U6), and water-mediated hydrogen 
bond interactions between the U6 O4 and the backbone amide of B: Ser 233 and the 
U6 O4 and N3 and OE (side chain carbonyl oxygen) of conserved B: Gln 94. Arg 132 
is held firmly in position by hydrogen bonding between Arg 132 NH1 and NH2 and 
conserved A: Asp 101 OD1 and OD2.  In addition, hydrogen bonds are observed 
between the U6 O2 and NH1 and NH2 of B:Arg 88 and between the ribose O4 and the 
NH1 of B:Arg 88. This would hold U6 firmly in position, and may serve as a means to 
stabilize negative charge on the base during methyl transfer. Arg 88, in turn, is held in 
place by interactions between its NH2 and NE and the OD1 and OD2 of conserved 
A:Asp 90. Asp 90 is the equivalent of the human Asp 96 that is mutated to glycine in 
Bowen-Conradi syndrome. That mutation would have the effect of destabilizing the 
interaction with the U6 substrate both through disruption of the interaction with the 
Arg 88 and hydrophobic contacts with Ile 91 through repositioning.  Finally C5 of the 
uridine base is positioned a mere 3.9 Å away from the sulfur atom of SAH, in perfect 
 
44 
position for a methyl transfer to the C5 position of the uracil (Fig. 4.3B). If a 
pseudouridine were in its place, then N1, which is an equivalent position to C5, 
would be the target of methylation. 
In the remaining consensus sequence, C7 is recognized through backbone 
interactions between the carbonyl oxygen, O2, and the backbone amides on either 
side of A: Arg 132, and a base stacking interaction with A: Arg 136. A8 is 
sandwiched between a stacking interaction with conserved A: Arg 129 and van der 
Waal’s contact with conserved A: Ile 159, and donates a hydrogen bond from N6 to 
the backbone carbonyl oxygen of A: Thr 127. A8 N6 is also involved in a water-
mediated hydrogen bond interaction with the side chain OH of Thr 127 and A8 N1 is 
in hydrogen bonding distance of the backbone amide of A: Arg 129. A9 is recognized 
through hydrogen bonds between the backbone carbonyl of A: Arg 129 and the N6, a 
van der Waal’s interaction between the side chain of A: Val 128 and the C2, and a 
stacking hydrophobic interaction with conserved A: Leu 140. Although Val 128 is not 
highly conserved, it is Val, Thr or Cys in other sequences, which would be able to 
maintain the interaction with A9 C2. Finally C10 is specified by two hydrogen bonds 
with conserved A: Arg 136, one between the Arg NH2 and the C10 N3, and the other 
between the Arg NE and C10 O2. There is also an interaction between the C10 ribose 
O2’ and the backbone carbonyl of A: Arg136. Arg 136 contacts C10 via three 
hydrogen bonds, U5 via two hydrogen bonds, and stacks in between A9 and C7. 
Consequently, Arg 136 is invariant in all sequences. In a functional analysis by 
Taylor et al., mutations of Arg 136, as well as Arg 88, Arg 129, and Arg 132 to Ala 
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all result in diminished RNA binding activity as measured by yeast three hybrid 
assays with consensus sequences (16).  
Of the eight bases that form the stem in canonical Watson-Crick base pairs, 
only one, G11, is contacted at the base by a protein residue. B: Glu 74 accepts a 
hydrogen bond from G11 N2, and contacts the G11 ribose O2’ via a water-mediated 
interaction (Fig. 4.5). Other backbone interactions between the protein and the RNA 
include contacts between A: Gln 143 and C10 O2’ and phosphate between C10 and A9, 
A: Arg 129 and C11 O2P, A: Arg 211 and the phosphate between U5 and U6. Of these, 
Arg 129 and Gln 143 are highly conserved, while Arg 211 is only weakly conserved 
(Fig. 3.1A). Based on this data, we can conclude that very little specificity is 
determined in the stem portion of the RNA.  
4.3: Catalytic Residues in the Active Site 
The methylation reaction that Nep1 catalyzes would require the deprotonation 
of N1 of the pseudouridine so that it could attack the methyl group from SAM. 
Stabilization of a negative charge on the uridine ring would result in a decrease of the 
pKa, which was measured at 8.97 for free pseudouridine (76). The likely candidate for 
this stabilization would be invariant Arg 88, for which both primary amine nitrogens 
are within hydrogen bonding distance of O2, the C2 carbonyl oxygen (3.3 and 2.8 Å); 
(Fig. 4.3B), and which is stabilized by bidentate hydrogen bond interactions with 
invariant Asp 90, which is mutated in Bowen-Conradi Syndrome (77). Mutation of 
Arg 88 to Asp resulted in a significant loss of Nep1 RNA binding activity (17). Arg 
88 and Asp 90 are located at the beginning of αA, and are surrounded by Pro 89 and 
Ile 91, which are also invariant. Ile 91 is in van der Waals contact distance of the 
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uridine ring in the active site. This region is labeled as the “Catalytic Loop” in Fig. 
3.1A and 3.1B. Arg 132 may also provide further stabilization, since it is also within 
hydrogen bonding distance (3.0 Å) of O2. These interactions would increase 
deprotonation at the N1 through localization of the negative charge to O2 where it 
would be stabilized by interaction or proton donation by Arg 88. This would in turn 
enable N1 to accept the methyl group from SAM.  
4.4: Free Nep1 vs Nep1 Bound to RNA 
When a monomer of free Nep1 is compared to monomers from the RNA 
Nep1 complex, an RMSD of 0.76 Å is observed for 415 out of 426 residues. Most of 
the interaction between the RNA and the protein are mediated by the helix αc’ and 
adjacent loops on the monomer that does not provide the SAM to the active site. 
However, the most significant conformational changes are seen in the small Nep1 
specific inserted domain on the SAM binding side of the dimer interface (Fig. 4.5A, 
B). This domain, consisting of a 3-10 helix (Hb’), small α-helix (αa’), and a β-
hairpin, undergoes a shift in positioning towards the dimer interface when RNA is 
bound. In addition, there is alteration of overall secondary structure, as the structure 
changes to accommodate interactions with the RNA (Fig 4.5A, B). The domain, 
which is packed against α4, houses Arg 88, which may be important for catalysis, and 
Glu 74 that interacts with G11. The buried surface area in the RNA bound structure 
(1338 Å2) is slightly decreased, due to an opening of the interface to accommodate 
the RNA, which buries an additional 721 Å2 on the monomer containing the methyl 
donor and 351 Å2 on the other monomer. 
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4.5: Two RNA vs One RNA 
Both the 1:1 and 1:2 (ScNep1 dimer:RNA) complexes for the complexes 
between Nep1 and RNA were obtained using the same preparation of Nep1 to RNA 
in a 2:2 (ScNep1 monomer:RNA) ratio. The isolation of these two complexes in the 
crystal structures suggests that both complexes exist in solution, which implies 
differences in the binding affinities between the two sites. Comparisons of the 
structures of these complexes reveal differences in the structures of the RNA binding 
sites as a function of occupancy with RNA (Fig. 4.5C, D). The RMSD for the 
alignment of the protein molecules in the complexes averages 0.85 Å for 421 residues 
of the protein chains, with the largest difference being between chain A of the 1:1 
complex and chain B of the 2:1 complex. This number is larger than the RMSD for 
the comparison between the Nep1/1RNA complex and the free enzyme, indicating a 
larger conformational difference between the Nep1/1RNA and Nep1/2RNA 
complexes than between the free enzyme and the Nep1/1RNA complex. Upon closer 
inspection, we observed that the positioning of one monomer relative to the other is 
slightly different between the two complexes. In the Nep1/2RNA complex, the two 
monomers are slightly closer together near the RNA binding site, indicating that RNA 
binding pulls the two monomers closer together. As a result, the SAH molecule is 
pulled closer to the RNA.  The SAH molecule is contacted mostly by backbone 
interactions, but one residue, Asp 214, hydrogen bonds the ribosyl 3’OH via one of 
its side-chain carbonyl oxygens (Fig. 4.6). In the Nep1/2RNA complex, for one 
monomer site the Asp 214 side-chain is rotated away from the SAM binding site and 
no longer contacts the bound SAM (Fig. 4.7A, B). This results in a slightly altered 
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positioning of the methionyl moiety in the active site, with the sulfur atom positioned 
farther away from the uridine base (Fig. 4.7A, B). In addition, the SAM binding 
pocket on the side of the dimer not bound to RNA in the Nep1/1RNA complex is not 
visibly occupied by SAH. Based on these observations, and the presence of additional 
conserved positive charged surface (Fig. 4.2), it is possible that both RNA binding 
sites would be occupied on rRNA, perhaps with varied binding affinity or specificity, 
and additional binding surface would be used to interact on the surface of the rRNA.  
4.6: Binding Assays with Nep1 and RNA  
	   Many attempts were made to determine the binding affinity of Nep1 to the 
target sequence. Electrophoretic mobility gel shift assay (EMSA) and anisotropy are 
described. For gel shift, a 12 base RNA oligonucleotide (5'-CUCUUCAACGAG-3') 
was radioactively 5' end-labelled with T4 polynucleotide kinase and [γ-32P]ATP using 
the KinaseMaxTM kit from Ambion. The labelling reaction was performed with 25 
pmol of RNA and 33 pmol of radioactive ATP, 1 µL of T4 polynucleotide kinase, 2 
µL of the provided 10 X kinase buffer, 13 µL RNAse free water and incubated at 37 
°C for one hour. After the incubation period, 1 mM EDTA was added and the 
reaction was halted via heating at 95 °C for two minutes. Labelled RNA was added to 
a reaction mixture of ScNep1 in varying concentrations from 1.2 x 10-4 M to 2.4 x 10-7 
M in buffer containing 3 % glycerol, 75 mM NaCl, 2 mM MgCl2, 50 mM Tris pH 
7.5, and 0.1 % BME and allowed to incubate at 25 °C for one hour.  After incubation, 
the reaction was stopped via heat denaturation and ran on a 6 % TBE polyacrylamide 
gel. All gels were run in triplicates, gel dried, exposed to a phosphor screen and 
scanned with a StormTM Imager. Quantification of bands was performed with 
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ImagequantTM. Figure 4.8A presents an example gel with ScNep1 concentrations 
showing weak binding, which conflicts with reports from M. jannaschii Nep1 
fluorescence experiments performed by Wurm et al. (22). Upon performing the same 
experiment with a control RNA oligonucleotide with sequence 5'-
UGUGUGUGUGUG-3' and obtaining nearly identical results, it appeared Nep1 had 
the ability to non-specifically bind short RNA oligonucleotides.  
 Fluorescence anisotropy measurements were made on the Fluorolog-3 Jobin 
Yvon Horiba fluorescent spectrophotometer set at 4 nm bandwidth and 1 second 
integration times. 5’-Fluorescein (Fl) labeled RNA  (5'-Fl-CUCUUCAACGAG-3') 
and 3'-Fl labeled control RNA (5'--UGUGUGUGUGUG-Fl-3') was used for the 
binding assay.  10 nM labeled RNA was added to 1 mL of solution containing 
ScNep1, 75 mM NaCl, 50 mM Tris pH 7.5, 2 mM MgCl2, and 0.2 % BME.  A 
titration curve was obtained by removing 200 µL of solution and replacing 200 µL 
with dilution buffer containing 75 mM NaCl, 50 mM Tris pH 7.5, 2 mM MgCl2, and 
0.2 % BME, and 10 nM labeled RNA. The dilution buffer contained 10 nM labeled 
RNA to keep oligonucleotide concentration consistent throughout the entire titration 
curve.  The reaction was done at temperature controlled 25 °C with constant stirring.  
Measurements were taken 8 minutes after every dilution to allow temperature and 
concentration equilibration with excitation at 495 nm and emission spectra averaged 
from 518-522 nm. The results of anisotropy reflected those seen in gel shift.  Nep1 
bound both the control RNA and target RNA with nearly identical affinity.  Figure 
4.8B shows an example of raw anisotropy data from control RNA. Anisotropy data 
could not be fit to an acceptable model.  Both experiments described here suggest 
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Nep1 non-specifically binds to short RNA oligonuclotides. While, this is not ideal for 
measuring specific affinities of the target sequence, it does provide support that 
Nep1's additional positive surface can bind additional RNA (Fig. 4.2), which is 
expected given Nep1's environment around the 18S rRNA. 
4.7: Chapter Summary 
The detailed structural description of the active site and all interactions 
associated with the binding of the target RNA presented in the two bound structures 
results in an understanding of Nep1’s ability to methylate pseudouridine. Through 
structural analysis, it is possible to present mechanistic insights including the role of a 




Figure 4.1: Overall Structure of the Nep1/RNA Complexes  
Structures of the A) one RNA and B) two RNA complexes with SAH (pink) and 




Figure 4.2: Electrostatic Surface of Nep1/1RNA Complex 
Electrostatic surface of the Nep1 complex showing front, top and bottom views. The 
surface is colored red to blue, negative to positive charge (calculated using vacuum 




Figure 4.3: Nep1-RNA Interactions 
A) Stereo figures of RNA bound in the cleft between the two monomers. Residues are 
colored according to monomer from which they originate (green-monomer A; cyan-
monomer B). Dash lines represent connections between atoms within hydrogen 
bonding distance. RNA (magenta) truncated to show only the bases that contact the 
protein for simplicity. B) Stereo view of a close-up of the uridine base interactions 
with 2Fo–Fc map contoured at 1σ. Protein residues are colored as in (A). U6 is shown 




Figure 4.4: Schematic of Interactions Between Nep1 and RNA 
Shown here is a diagram of the interactions between the crystallized RNA stem- loop 
and Nep1 residues (colored text; blue = monomer B; green= monomer A). Red 
arrows indicate possible hydrogen bonds and black lines terminated by black dots 




Figure 4.5: Conformation Changes Upon RNA Binding 
A) Front and B) Bottom views of the Nep1/1 RNA complex (green-monomer A, 
cyan-monomer B) superposed on the free dimer (magenta). C) Front view of the 
alignment of the 1 RNA and 2 RNA (yellow) complexes. D) Bottom view of both 
RNA complexes and the free dimer. Monomer B, shown here on the right, was used 
to align the monomers. Asterisk indicates the Nep1 specific domain where significant 
structural change occurs, and αc' indicates the RNA-binding helix that shifts relative 




Figure 4.6: Interactions with SAH 
Shown here are the interactions holding SAH (yellow) in the active site with 2Fo–Fc 
map contoured at 1σ. Protein residues are colored as in cyan and U6 is shown in 





Figure 4.7: Alignment of SAM Binding Pockets 
A) Alignment of the SAM-binding pockets of Nep1/1RNA complex monomer B 
(cyan), Nep1/2RNA monomer B (green), Nep1/2RNA monomer A (magenta) and 
free Nep1 dimer (orange) showing side chains of residues that show the most 
conformational differences between the complexes. Spheres indicate bound waters, 
and are labeled ‘W’. B) Stereo view of the alignment of SAM binding sites in the 
Nep1/1 RNA and 2 RNA complexes. Nep1/1RNA monomer B and Nep1/2RNA 




Figure 4.8: Nep1 and RNA Binding Assays 
A) StormTM scan image from phosphor screen of ScNep1 and target RNA (5'-
CUCUUCAACGAG-3') electrophoretic mobility gel shift assay. B) Anisotropy data 
taken from Fluorolog-3 Jobin Yvon Horiba fluorescent spectrophotometer of ScNep1 
binding to control RNA (5'-UGUGUGUGUGUG-Fl-3'). 
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Chapter 5: Nep1 Discussion and Conclusions 
5.1: Overview 
The four deposited structures provided a leap forward in understanding the 
role of Nep1 in ribosome biogenesis, specifically contributing to a molecular view of 
the interaction with target RNA.  This work supports previous research suggesting 
Nep1 as a pseudouridine methyltransferase along with a second function that is 
essential for cell survival (21, 22). This chapter provides discussion and conclusions 
based on the information gained from the analysis of AfNep1, ScNep1 free, and 
ScNep1 bound to one and two molecules of target RNA. 
5.2: Nep1 Project Discussion and Conclusions 
Prior to this work, the structures of the ScNep1 in monomeric form, and the 
archaeal M. jannaschii Nep1 dimer, allowed for the classification of Nep1 as a 
SPOUT methyltransferase, characterization of the Nep1 specific structural elements 
and analysis of the SAM binding pocket, and, in combination with mutagenesis and 
NMR mapping on the M. jannaschii Nep1, allowed for a prediction of the RNA 
binding site (16, 17, 22, 78). This report provides a view of dimeric ScNep1 in apo 
form and in complex with RNA, allowing a first look at a SPOUT methyltransferase 
bound to RNA, a high resolution analysis of the interactions of the only known N1-
specific pseudouridine methyltransferase with a substrate analog, and a picture of the 
RNA structure that Nep1 stabilizes upon binding. These data confirm that the RNA 
binds to the cleft between the two monomers, which agrees with previously reported 
NMR mapping data and mutational analysis that reported mutation of the M. 
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jannaschii equivalents of R88, R129, R132 and R136 significantly reduced RNA 
binding activity (16, 22). In Nep1, the binding site accommodates a stem-loop 
structure, with the majority of binding observed between the RNA loop and the 
protein. Both the RNA three-hybrid screening of ScNep1 and the specificity 
determination on M. jannaschii Nep1 indicate that Nep1 binds more tightly to a 
predicted stem-loop structure, suggesting that this is the preferred substrate for Nep1 
(21). However, for M. jannaschii Nep1, sequences that do not contain a stem can also 
bind (21, 22).  We have no information about the structure of the free RNA, and no 
similar loops containing this sequence were found in the structure databases, but the 
stem-loop is predicted to form at 37 °C by RNAfold (79), although we are not sure if 
U6 would be flipped out in the absence of protein. The RNA seen in our structures 
fails to contact much of the positively charged surface of the protein, leaving open the 
possibility that the actual binding site is larger than the selected consensus sequence.  
It has been proposed that Nep1 is the first example of an N1-specific 
pseudouridine methyltransferase and that it catalyzes the only such modification 
known in 18S rRNA, the N1-methylation on the hypermodified m1acp3Ψ at position 
1191 in yeast (22). The structural evidence, seen in the specific positioning of the C5 
of uridine in the enzyme active site, supports this. The uridine is held in place by 
several contacts that impart this specificity, and the interaction with Arg 88 suggests 
that this residue plays a role in catalysis, by promoting deprotonation of the ring (Fig. 
5.1). Asp 90, which is equivalent to Asp 86 that is mutated in Bowen-Conradi 
Syndrome, also plays a role by holding Arg 88 in place in the structure. There are no 
candidates for direct hydrogen binding near the C5 of the uridine in our structure that 
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may allow specific selection of pseudouridine, but the absence of an activating 
nucleophile in the vicinity of C6 in these structures rules out the possibility that this 
protein functions as an m5U methyltransferase, as would be suggested if uridine was 
the substrate (80, 81). In addition, m5U modification has not been observed in yeast 
18S rRNA. However, this means that uridine is indistinguishable from pseudouridine 
in the Nep1 active site, but it will only catalyze methyl transfer on pseudouridine. 
This is supported by fluorescence binding data for M. jannaschii Nep1 reported by 
Wurm et al. that shows no significant differences in RNA binding Kd when 
pseudouridine is replaced with uridine in high affinity RNA binding sites (22). 
Although it is likely that the N1-methyltransferase activity is important for 
Nep1 function, as supported by the severe defect caused by mutations at Asp 90, it 
has been reported that mutations in the SAM binding site of Nep1 that reduces its 
ligand binding activity by 100 fold results in no disruption of Nep1 activity (17). 
Therefore it is plausible that binding of Nep1 to the rRNA in the absence of methyl 
transfer activity is sufficient to carry out at least some of its role in ribosome 
biogenesis. In addition, overexpression of yeast ribosomal protein Rps19 
compensates for deficiency in Nep1 function (21). An explanation put forth for these 
observations was that Nep1 might play a role that is independent of Nep1 
methyltransferase activity (17, 21). A possible role may be to act as a chaperone of 
RNA folding during a specific assembly step. The observation of a two RNA 
complex in which both binding sites are occupied suggests that it is plausible that 
rRNA occupies both sites when Nep 1 binds in vivo. Based on structural analysis, the 
two binding sites are non-equivalent, highlighted by differences in binding to SAH 
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(Fig. 4.7A, B). This idea that both sites would be occupied in the ribosome is further 
supported by the presence of extensive positively charged surface not contacted by 
the stem-loops in the structures. Two of the three possible Nep1 binding sites in yeast 
18S rRNA are located within 50 Å of each other in the 3-dimensional structure of the 
eukaryotic ribosome (Fig. 5.2A) (30) (82). Those sites are the loop terminating helix 
31 and a portion of helix 42 (Fig. 1.2 p12). Based on the EM reconstruction of the 
eukaryotic ribosome (30) and the recent crystal structure of the complete yeast 
ribosome (82), in order for Nep1 to bind the site at helix 42, significant secondary 
structure alteration would have to occur (Fig. 5.2B; Fig 1.2 p12; Fig. 5.3). Half of the 
expected stem loop that is expected to form when Nep1 binds is part of helix 42. 
Therefore, it is possible that when Nep1 binds, there is a rearrangement of the 
interactions to produce the expected stem-loop (Fig. 5.3C). This rearrangement would 
also result in the two Nep1 sites being moved closer together, since the distance 
between active sites in the Nep1 dimer is ~20 Å, while it is shown to be 50 Å apart in 
the mature rRNA (30). The loop at the end of helix 42 interacts with the loop of helix 
41 (Fig. 5.2B). Helix 41 is the site of most of the contacts between the rRNA and S19 
(Fig. 5.2B & Fig 1.2 p12). Therefore, a possible model is that Nep1 interacts with the 
rRNA at two sites – the loop of helix 31, where it catalyzes the methylation of Ψ1191 
and the stem of helix 42, where it acts as an RNA chaperone and breaks apart helix 
42, rearranging the area and the interactions with helix 41 to promote S19 binding. In 
this scenario, more of the Nep1 surface would be expected to contact rRNA, as 
predicted by this structure. This is assuming that rRNA in early maturation stages 
have structures near the predicted structure of the mature rRNA. However, there is 
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evidence that pre-rRNA structure can differ from mature rRNA structure (83). In the 
absence of snR57, which is predicted to bind between bases 1568 and 1584, a Nep1 
deletion is no longer lethal, indicating that Nep1 is only required when snR57 is 
present (21). Since snR57 guides the methylation of G1572 (29), a site near helix 42 
(Fig. 1.2 p12), this interaction between Nep1 and snR57 may be due to structural 
changes that occur as a result of methylation. Another possibility, however, is that the 
interaction between Nep1 and its binding site in that region may promote the 
dissociation of snR57 from rRNA. This dissociation may be necessary for proper 
rRNA structure, or even for N7 methylation of G1575 catalyzed by Bud23p (84).  In 
any case, the genetic interaction between the snR57 and Nep1 supports the possibility 
of Nep1 binding in the region near helix 42.  
M. jannaschii Nep1 binds to yeast 18S rRNA sequences corresponding to the 
loop of helix 31 (78), and AfNep1 similarly is capable of binding yeast rRNA 
sequences corresponding to the Nep1 binding site near helix 42 (data not shown). 
Residues involved in key interactions with the RNA, for example Arg 88, Arg 136, 
Arg 129, Leu 140 and Leu 159, are identical in AfNep1. Superposition of the archaeal 
dimer on the yeast structures showed that the RNA interaction mode is likely to be 
very highly conserved between archaea and yeast (Fig. 5.4). Although these structures 
do not provide all the answers on Nep1 function, it does provide the basis for 




5.3: Hypothesis of Nep1's Role in Ribosome Biogenesis   
Taking	  all	   the	   information	  presented,	  a	  hypothesis	   for	  Nep1's	  role	   in	  ribosome	  
biogenesis	  can	  be	  suggested.	  For	  Nep1	  to	  bind	  both	  target	  sites	  in	  helix	  	  31	  and	  
helix	   42,	   there	   must	   be	   a	   major	   conformation	   change	   in	   helix	   42	   (Fig.	   5.5)	  
bringing	   the	   two	   active	   sites	   closer	   together.	   	   I	   propose	   Nep1's	   main	   role	   in	  
ribosome	   biogenesis	   is	   to	   facilitate	   this	   conformational	   change	   and	   chaperone	  
the	  folding	  of	  the	  immature	  pre-­‐rRNA	  into	  the	  essential	  structure	  needed	  for	  the	  
loading	  of	  ribosomal	  protein	  S19	  to	  helix	  41,	  which	  is	  in	  direct	  contact	  with	  helix	  
42	   in	   the	  mature	  18S	   rRNA.	  Furthermore,	   I	   propose	  Nep1	  preferentially	  binds	  
helix	  31	  prior	  to	  the	  target	  sequence	  of	  helix	  42.	  This	  will	  set	  Nep1	  in	  position	  to	  
dissociate	  snr57,	  making	  room	  for	  Nep1's	  interaction	  with	  helix	  42.	  Finally,	  after	  
S19	   is	  properly	   loaded,	  Nep1	   is	  disassociated	   from	  the	  ribosome	  caused	  either	  
by	  the	  rearrangement	  of	  helix	  42	  as	  seen	  in	  the	  final	  18S	  rRNA	  structure.	  
5.4: Future Directions 
	   In order to further understand the role of Nep1 in ribosome biogenesis, 
questions persist surrounding the proposed chaperone function. The ScNep1/1RNA 
and ScNep1/2RNA complex structures shows that Nep1 can bind RNA 
simultaneously on both sides of the dimer, but its still unknown if this does indeed 
happen simultaneously. Does Nep1 preferentially bind one target before the other or 
do both sites bind at the same time? Next, Does Nep1 direct a major conformational 
shift in helix 42 that results in the dissociation of snr57 and the subsequent loading of 
S19? To look at these questions, I believe work must shift from short RNA 
oligonucleotides to longer sections of the 18S rRNA that encompasses both Nep1 
 
65 
target sites and the location of S19 binding. Utilizing a longer section of the 18S 
rRNA in different binding assays that includes structural biology from both x-ray 
crystallography and NMR, RNAse secondary structure foot printing and fluorescence 
binding assays, could provide needed answers to these important questions.  Finally, 
small angle x-ray scattering (SAXS) is currently an emerging field and may provide 
an ideal technique in the near future for visualizing the proposed rearrangements of 




Figure 5.1: Proposed Nep1 N1-pseudouridine Methyltransferase Mechanism 
Putative mechanism for the transfer of a methyl group to the N1-position of 




Figure 5.2: Possible Role for Nep1 in S19 Loading 
A) and B) Three dimensional structure of the head region of eukaryotic 18S rRNA, 
truncated to remove bases 1212–1439 for simplicity. (A) and (B) were generated 
from PDB ID 3JYV [cryo-EM model of the 40S subunit of the Thermomyces 




Figure 5.3: RNA Structures in Nep1 Binding Sites 
A) Structure of RNA in Nep1 complex with schematic of the secondary structure 
shown on the right. B) Structure of Nep1 site at helix 31 and C) helix 42 (from the 
cryo-EM reconstruction of the eukaryotic ribosome (30)). Secondary structure 
predicted to be induced upon Nep1 binding shown on the right. For all figures, the 
consensus binding site is colored yellow and the * indicates the uracil inserted in the 




Figure 5.4: AfNep1 and ScNep1 Aligned with Sequence Conservation 
Stereo view of ScNep1 (cyan) bound to one RNA molecule aligned to AfNep1 (with 
symmetry mate to form dimer), colored to show conservation of the RNA binding site 
between archaeal and eukaryotic Nep1 proteins (red = identical; green = highly 




Figure 5.5: Proposed Chaperone Role of Nep1 in Ribosome Biogenesis 
Model of the proposed role of Nep1 in ribosome biogenesis highlighted by Nep1's 
ability to bind both target sequences simultaneously and chaperone the folding of 
helix 42, which will allow the loading of S19 to helix 41.   
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Chapter 6: Purification of Rio3 
6.1: Overview 
Rio3 is an atypical kinase with an unknown function and unknown structure.  
By sequence analysis with other family members, Rio3, known as RioK3 in humans, 
possesses a conserved RIO domain and an extended N-terminal domain of 
approximately 200 amino acids (35, 37, 39, 48). The goal of this project was to solve 
the crystal structure of the RIO domain for RioK3.  The full-length construct (519 
residues) suffered from insolubility problems when expressed in E. coli. Therefore, 
the focus of research was spent trying to express, purify, and crystallize a shortened 
construct containing only the RIO domain of RioK3 (residues 193-519). Presented in 
this chapter is the best purification protocol for the RIO domain of RioK3 and for the 
N-terminus of RioK3.  Initial crystallization trials from the resulting protein acquired 
from this purification protocol are also described in this chapter. 
6.2: Purification of RioK3   
The human shortened RioK3 gene (residues 193-519) with an N-terminal 
TEV cleavage site was PCR amplified using sequence specific primers (5'-
GAGAACCTGTACTTCCAGGGAATGGATTTAAAACTATCAAAC-3' and 5'-
GGGGACCACTTTGTACAAGAAAGCTGGGTTATCATTCATCATATAGTAGT
GGTGGGTC-3') and recombined into pDONR201 utilizing Invitrogen’s GatewayTM 
technology. The resulting plasmid was sequenced and confirmed the correct sequence 
for the shortened RioK3 construct with N-terminal TEV cleavage site. The plasmid 
was recombined into pDest527 designed with an N-terminal 6X-His tag (plasmids 
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obtained from Protein Expression Laboratory, SAIC, Frederick, MD).  RioK3-Short 
construct was transformed into E. coli Rosetta BL21-DE3-pLysS cells via heat shock.  
The construct was expressed in 1 L LB broth containing ampicillin (100 µg/ml) and 
chloramphenicol (34 µg/ml) at 37 °C until the optical density of the cells reached 0.5 
(approximately 4 h).  At the correct cell density, the cells were transferred to 20 °C 
incubator/shaker and allowed to cool before induction. The RioK3-Short construct 
was induced with 1 mM isopropyl thio-β-D-galactoside (IPTG) and grown overnight 
(16 h) at 20 °C, shaking at 250 rpm.  Cells were harvested by centrifugation and cell 
pellet was frozen overnight at -80 °C.  The frozen pellet was resuspended in 50 mL 
lysis buffer containing 500 mM NaCl, 50 mM Tris pH 8.0, 0.2% β-mercaptoethanol 
(BME), 2 mM MgCl2, 1 mM adenosine triphosphate (ATP), 0.1 mg/ml DNase1 
(Roche), 10 µg/ml RNaseA (Roche), and 0.1 X Bugbuster (Novagen) per liter of 
culture.  The resuspended pellet lysed on ice after stirring for 1 h.  The lysate was 
transferred to centrifuge tubes and the cell debris was spun down at 17000 rpm in 
Beckman preparative (rotor: Beckman 45 Ti) ultracentrifuge for 40 minutes at 4 °C.  
The supernatant was collected through a 0.22 µm filter.  The supernatant containing 
the soluble RioK3-Short construct was loaded onto an equilibrated 5 mL GE 
Healthcare HisTrap HP column using the BioRad Duoflow FPLC. The column was 
equilibrated with buffer A containing 500 mM NaCl, 50 mM Tris pH 8.0, 0.2% BME, 
2 mM MgCl2, 1 mM ATP.  The bound RioK3-Short construct was washed 
extensively with buffer A (>10 column volumes) followed by another extensive wash 
including 100 mM imidazole.  RioK3-Short was eluted from the column using a 
linear gradient from 100 mM imidazole to 1 M imidazole over ten column volumes.  
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The fractions containing RioK3-Short were combined and set up in dialysis 
membrane with buffer A and 2 mg TEV protease.  The cleaved protein was loaded 
back onto the 5 mL HisTrap column.  The RioK3-Short protein did not come through 
in the flowthrough: 20 mM imidazole in buffer A was needed to elute the bound 
protein.  The fractions containing RioK3-Short protein were pooled together and 
concentrated to a final volume of 3 mL.  A Superdex 200 16/60 size exclusion 
column was equilibrated with buffer A and the Rio3-short protein was passed over 
the column as a final purification step.  The fractions containing purified RioK3-Short 
protein were combined and concentrated to 15 mg/ml for crystallization.  All steps of 
purification were analyzed for purity by SDS-PAGE (Fig. 6.1).  Table 6.1 shows the 
RioK3 constructs that were expressed for purification and crystallization trials. 
6.3: Initial Crystallography of RioK3-Short 
The purified RioK3-Short construct was concentrated to 15 mg/mL and 
immediately screened for crystals using the Art Robbins PhoenixTM liquid handler. 
The sitting drop 96 well 3-well Intelliplate was chosen for screening with conditions 
known to promote crystallization. These varying conditions are combined into the 96 
deep-well format and were purchased from Qiagen (PEGTM Suite, CryosTM Suite), 
Emerald Biosystems (Wizard 1TM, Wizard 2TM, Wizard 3TM, NatrixTM) and Hampton 
Research (IndexTM). The 3-well format of the intelliplate allowed for a concentration 
range for each condition by setting up the sitting drops in 1:2, 1:1 and 2:1 protein:well 
solution ratios. In total, the initial crystallization screen for RioK3-Short consisted of 
1,152 different drops. Of those 1,152, one condition yielded extremely small 
(~5x30µm) protein crystals shown in Figure 6.2A. The crystals grew in 25% PEG-
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3350, 0.1 M HEPES pH 7.5, 0.2 M MgCl2. Those crystals were reproducible from 
protein expressed in minimal media (described in chapter 7) via the hanging drop 
method (Fig 6.2B) and sent to the NECAT APS beamline at Argonne National labs 
for testing of diffraction. This work was promising, yielding diffraction to ~5.5 Å 
shown in Figure 6.3. 
6.4: Expression and Purification of the N-Terminus of RioK3 
While working on the purification and crystallization of the RioK3 RIO 
domain, the N-terminus of RioK3 was shown to bind to polyubiquitin (85). N-
terminal fragment 16-153 was shown to bind to Lys-48 linked and Lys-63 linked 
Ubuitin (85). RioK3 does not possess a known Ubiquitin binding domain, which 
suggests RioK3 could bind Ubiquitin via a novel mechanism. Using Invitrogen 
GatewayTM cloning, RioK3-1-153 and RioK3-1-193 were cloned with an N-terminal 
histidine tag followed by a TEV cleavage site with forward sequence (5'-GAGAAC 
CTGTACTTCCAGGGCATGGATCTGGTAGGAGTGGCATCG-3' and reverse 
primers 5'-GGGGACCACTTTGTACAAGAAAGCTGGGTTATCACTTTTTAGG 
AGTGGGAACCGGTTT-3' and 5'-GGGGACCACTTTGTACAAGAAAGCTGGG 
TTATCAAATTCCATCTCCTACCTGAAACTC-3', respectively. After unsuccessful 
purification attempts due to insolubility, RioK3-1-193 was recombined into pDest566 
with maltose binding protein (MBP) as an N-terminal fusion protein resulting in 
HIS6-MBP-TEV-(RioK3-1-193). The fusion protein was used to improve solubility. 
The expression and purification scheme was similar to RioK3-Short with two 
modifications.  First, the lysis and size exclusion buffers contained 200 mM NaCl, 50 
mM Tris pH 8.0 and 0.2 % BME. The elution buffer contained 200 mM NaCl, 50 
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mM Tris pH 8.0, 0.2% BME and 1 M imidazole. Second, after TEV cleavage MBP-
RioK3-1-193 did not require 20 mM imidazole for elution and came out as expected 
in the flowthrough. All steps of purification were analyzed by SDS-PAGE and shown 
in Figure 6.4. The successful purification of the N-terminus of RioK3 provides a great 
starting point for the next researcher to look at interactions with Ubiquitin. 
6.5: Chapter Summary 
The initial crystallography results showing diffraction from crystals acquired 
from the purification protocol presented in this chapter was very promising. The 
crystals were reproducible and they diffracted! This beginning success provided a 





Figure 6.1: RioK3-Short Purification Gels 
A) SDS-PAGE of RioK3-short after first pass over GE Healthcare HP affinity column 
(IN=induced sample, Sol=supernatant after lysis, FT=flowthrough, TEV Trial=20uL 
elutant incubated with 20 µL TEV protease (1 mg/mL) for 30 minutes on rocker and 
ran as lane 8, Tag=histidine tag cleaved during TEV trial). B) RioK3-Short after 
cleavage passed over affinity column to remove tag and uncleaved protein (B=before 
cleavage, A=after cleavage). Concentrations indicate amount of imidazole required 
for elution from column. C) Elution from GE Healthcare Superdex 200 16/60. 









Figure 6.2: RioK3-Short Crystals 
A) First Riok3-Short crystals obtained from G12 of the IndexTM screen in the 2:1 
protein:screen ratio. B) Reproduced crystals from RioK3-Short grown in minimal 
media. Diffraction of crystals from (B) screened at the synchrotron resulted in 




Figure 6.3: Diffraction of RioK3-Short 
Diffraction image of a RioK3-Short crystal grown in minimal media, collected at 




Figure 6.4: MBP-RioK3-1-193 Purification 
A)	  SDS-­‐PAGE	  of	  MBP-­‐RioK3-­‐1-­‐193	  after	  first	  pass	  over	  GE	  Healthcare	  HP	  affinity	  
column	  B)	  Cleaved	  RioK3-­‐1-­‐193	  was	  passed	  over	   the	   affinity	   column	  a	   second	  
time	   and	   collected	   in	   the	   flowthrough.	   This	   gel	   shows	   effiicient	   cleavage	   after	  




Chapter 7: Optimization of RioK3 
7.1 Overview 
The crystals acquired from the RioK3-Short construct and purification 
protocol presented in chapter 6 provided the first look at diffraction. The 5.5 Å 
resolution diffraction however, does not provide enough resolution to acquire a 
solution, either by de novo phasing or by molecular replacement. This chapter will 
describe the many methods used to optimize RioK3 in order to acquire strong enough 
diffraction for structure solution.  
7.2: General Optimization Methods 
7.2A: Precipitant, pH, Temperature, Salt, Protein Concentration/Ratio Optimization  
The first method of optimization is always setting up conditions that vary the 
original crystal condition discovered during initial screening, in this case IndexTM 
G12. For RioK3-Short, this general optimization method was performed methodically 
varying the precipitant concentration (16-30% PEG-3350), buffer pH (0.1 M HEPES 
pH 5.5-9.0), and salt concentration (0.1-0.4 M MgCl2) independently of each other in 
a 24-well hanging drop Qiagen Cryotool (crystal plate).  Also, concentration of 
RioK3-Short ranged from 8-30 mg/ml, as crystal size and quality can vary greatly 
depending on protein concentration. The temperature of crystal tray incubation was 
performed at 20°C or 4°C. The goal of the optimization was to acquire bigger, more 
defined crystals. However, these methods of optimization did not work.  There was an 
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excess of precipitation in the hanging drops in nearly every condition. What was 
causing this precipitation and lack of crystal formation?  After trial and error and 
multiple rounds of purification and optimization trays, the reason for this instability 
became clearer.  RioK3-Short was unstable and precipitated when diluted from its 
original purification buffer containing high salt (500 mM NaCl), high ATP 
concentration (1 mM) and 2 mM MgCl2. To counteract this dilution, I chose to 
develop a method of setting up drops that would create a range of dilution (Fig 7.1A). 
An “X” of concentrated protein (4 µL) was created using a pipette tip.  At the center 
of the formed “X”, 1 µL of precipitant was added, this is depicted in Figure 7.1A. If 
the dilution of original condition were the cause of the instability, then this “X” 
method would show heavy precipitation in the middle, crystals in the precipitation 
interface (also known as the metaphase), and finally soluble protein without crystals 
towards the edges of the “X”.   As seen in Figure 7.1B, this method confirmed 
RioK3-Short becomes unstable as the original conditions are diluted.  Also, this “X” 
method of setting up drops, yielded many clean crystals and provided reasoning to set 
up unconventional ratios of protein:precipitant that was later optimized to 6:1.  
Although bigger, cleaner crystals were obtained by general optimization, the 
diffraction was limited 6.0 Å.  
7.2B: Minimal Media/ Minimal Media with Se-Met 
Before changing the construct and introducing mutagenesis, another form of 
optimization is to modify the method of protein expression. This can be done through 
expression in minimal media and minimal media containing selenium methionine 
(Se-Met).  Along with experience seen in the lab, trends in literature and recognizing 
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examples at conferences, there is ample supporting evidence that expression in 
minimal media can improve crystal quality and diffraction (86, 87).  It is still unclear 
and not yet in literature what is the cause of this improvement, but the current 
hypothesis is the minimal media slows expression and promotes more precise protein 
folding resulting in a more homogenous protein for better, tighter crystal growth.  The 
presence of a strong diffracting heavy atom (Se-Met), introduced during expression, 
may also improve diffraction.  RioK3-Short was grown in minimal media and also in 
minimal media containing Se-Met. Bigger cleaner crystals were obtained in minimal 
media (Fig 6.2B) and resulted in the 5.5 Å diffraction pattern shown in chapter 6 
Figure 6.3. The diffraction pattern was indexed with DENZO, part of the HKL2000 
program suite, where the point group and unit cell dimensions were determined (Fig 
7.2A, B) (56). The unit cell was enormous with dimensions of a=142.0, b=142.9, 
c=273.5 in the primitive hexagonal point group later determined to be space group 
P32 during scaling with Scalepack, which is also packaged into HKL2000 (56). Table 
7.1 shows the data logfile from Scalepack from a near complete dataset collected 
from a RioK3-short crystal (Fig 6.2B) grown in minimal media.  
Although high symmetry is present in the crystal, the Matthews Coefficient 
(MC) calculation suggests between 13-23 (most likely 18) molecules in the 
asymmetric unit (88, 89).  The MC program uses the space group and unit cell 
dimensions to calculate a total volume in the cell. After calculating the total volume, 
the program then uses the expected molecular weight of the protein and predicts the 
percentage of solvent in the asymmetric unit, or in other words, the specific volume 
(Matthews Coefficient) contributed from the inputted protein molecular weight. Table 
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7.2 shows Matthews Coefficient output logfile with the number of monomers possible 
in the asymmetric unit ambiguously between 13-23 monomers corresponding to a 
solvent content from ~35%-65%. The most common percentage of solvent found in 
the PDB database is 47% solvent, which corresponds to 18 or 19 monomers for 
RioK3-Short (89). The oversized unit cell and low resolution diffraction combined 
with calculations to predict the large number of monomers in the asymmetric unit 
suggests RioK3-Short crystals were disordered and not packed very tightly.  The goal 
of optimization from this point was to shrink the unit cell and promote tighter crystal 
packing.   
7.2C: Crystal Manipulation (Annealing, Dehydration, Seeding) 
Crystallography techniques that involve physical manipulation of already 
grown crystals include annealing, dehydration and seeding.  Annealing of crystals is 
used to eliminate possible disruptions in crystals lattices caused by freezing (90, 91).  
Cryogenic conditions are supplemented to crystal conditions to protect crystals during 
freezing, which is required before shooting with high energy x-rays; however, 
sometimes even in the presence of a suitable cryogenic condition freezing still causes 
deformation and disorder in the crystal. Specifically, freezing can cause an expansion 
of the solvent in the crystal and cause disordered crystal packing resulting in poor 
diffraction.  Annealing is the process of warming the crystal to room temperature 
after flash freezing.  Two types of annealing were performed with Riok3-Short 
crystals. The first, known as annealing on the loop, consists of blocking the 
cryostream while the crystal is mounted on the goniometer just long enough to thaw 
and then flash refreeze by unblocking the cryostream (91). This method destroyed 
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nearly all diffraction; leaving just smeared diffraction, which are common in severely 
damaged crystals. The second, known as macromolecular crystal annealing, was 
performed by removing a crystal from the cryostream and placed back into the crystal 
condition containing 20% ethylene glycol for five minutes (91). After sitting for five 
minutes, the crystal is then looped again and flash frozen. This method of annealing 
also did not improve diffraction. 
Dehydration is performed for a completely different reason than annealing.  
Dehydration is used to remove water molecules from the crystal in order to shrink the 
unit cell (91, 92). This method was very appealing for RioK3-Short because of the 
enormous unit cell observed in previous diffraction data. Dehydration was performed 
via variations of two general methods (91). One method is replacing water molecules 
with a step-wise increase of dehydration agents, allowing the crystal to equilibrate at 
each step. Dehydration agents used for Riok3 were glycerol, ethylene glycol and 
PEG-3350. Crystals of Riok3-Short were looped and transferred to mother liquor 
(original crystal condition) plus 5% dehydration agent and allowed to sit for 5 
minutes. Once equilibrated, the crystal was looped again and transferred to mother 
liquor plus 10% dehydration agent.  These 5% dehydration agent jumps and 
incubation steps were continued until dehydration agent reached mother liquor plus 
30%.  One crystal was allowed to rest overnight in the final 30% for each dehydration 
agent.  This method of dehydration requires very robust crystals that can withstand a 
large amount of manipulation. RioK3-Short crystals did not appear to break down or 
become damaged during transfers. The other method of dehydration involves a single 
step allowing air to dehydrate crystals by evaporation of water molecules in a 
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reservoir of mother liquor containing the appropriate cryo condition and/or increased 
precipitant. RioK3-Short crystals were exposed to air for thirty minutes or one hour in 
100 µL reservoirs containing mother liquor plus 20% ethylene glycol, mother liquor 
plus 10% PEG-3350, or mother liquor plus 10% ethylene glycol and 10% PEG-3350.  
Unfortunately, the diffraction of crystals from either method of dehydration did not 
improve diffraction.  
All annealing and dehydration experiments were performed on the University 
of Maryland’s Bruker home source macromolecular diffraction system.  While the 
synchrotron is ideal to see small changes in diffraction quality, the home source was 
sufficient to determine if annealing or dehydration significantly improved diffraction, 
which did not occur.  
Finally, the last type of crystal modification performed on RioK3-Short was 
seeding. There were two types of seeding attempted, macroseeding and microseeding 
(91, 93, 94).  The names are very telling, as macroseeding is the process of looping a 
single large crystal, washing the crystal, and then placing the crystal for further 
growth in either an already equilibrated crystal condition or unequilibrated condition 
with fresh protein. Microseeding is pulverizing a small crystal into microscopic 
crystals, and then using a horse or cat whisker to transfer the microcrystals, or 
diluting the stock seed mixture, into an already equilibrated crystal condition below 
the precipitant concentration required for crystallization.  The goal of microseeding is 
to set up a range of conditions with a decreasing number of nucleation points 
(microseeds) by streaking across multiple drops much like sequentially streaking 
bacteria onto an agar plate, with the purpose of acquiring a single colony.  RioK3-
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Short was subjected to both types of seeding.  Microseeding did not yield any 
crystals, however macroseeding was successful in growing larger crystals. The larger 
crystals suffered from the same poor diffraction as the original pre-seeded crystals, 
with diffraction limited to ~6.0 Å when screened at the NECAT beamline. 
7.3: RioK3-S199A-Short 
Crystallography techniques to improve existing crystal diffraction were 
unsuccessful. Because RioK3-Short was soluble and a successful purification 
protocol was already determined, the next logical direction was the optimization of 
the RioK3-Short construct via site-directed mutagenesis. Pure RioK3-Short protein 
was sent previously for molecular weight determination via mass spectrometry at the 
University of Maryland Proteomics Core Facility managed by Dr. Yan Wang.  The 
expected molecular weight of RioK3-Short (193-519) is 37,717.2 Da. The resulting 
spectra confirmed the expected MW of RioK3-short with a peak centered at 37,717.6 
Da (Fig. 7.3A). A second peak centered at 37,794.7 Da suggested the presence of a 
singly phosphorylated version of RioK3-short because the difference between the two 
masses is the expected change for a post-translational phosphorylation modification. 
Excess protein was digested with trypsin and analyzed by tandem LC MS/MS by Dr. 
Yan Wang.  Peptide determination of the trypsin fragments identified 84% of the 
sequence with only one possible site for phosphorylation (Fig. 7.3B). The 
phosphorylated residue was serine 199.  Stratagene’s Quikchange Lightning Site-
Directed Kit was used to mutate serine 199 to alanine to abolish RioK3’s ability to 
autophosphorylate. RioK3-S199A-Short purified identically to RioK3-Short with no 
deviations.  Again, the S199A mutant was screened and surprisingly the same 
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condition in which RioK3-Short crystallized did not grow S199A crystals. Only one 
condition of 1152, containing 24% PEG-8000, 0.1 M Tris pH 8.0 and 0.2 M MgCl2, 
grew crystals (Fig 7.4A).  These crystals were optimized in the same manner as 
RioK3-Short and grew much larger (~50x500 µm) than anything previously acquired 
from RioK3-Short (Fig 7.4B). Even though the crystals appeared more ordered than 
the RioK3-Short crystals, the diffraction did not match that same visual improvement.  
In fact, diffraction images collected at the synchrotron were poorer and  provided data 
to ~8.0 Å. 
7.4: Surface Entropy Mutations 
Surface entropy reduction (SER) is an accepted practice for improving 
crystallization chances for hard to crystallize proteins (95, 96). After the failure to 
improve diffraction past 5.5 Å over all previous forms of optimization, the RioK3 
project needed a new crystal form, and SER could provide the change necessary to 
promote crystallization in a new form.  SER is achieved by mutagenesis of surface 
residues with high conformational flexibility and thus a high amount of surface 
disorder/entropy.  Mutation of these residues, which are typically lysine or glutamate, 
to alanine reduces this flexibility and reduces the entropy on the surface of the 
protein. The less disorder on the surface of the protein promotes tighter packing 
during crystallization, which leads to better diffracting, higher resolution crystals. It 
was shown that sequential mutations of residues directly next to each other improves 
the likelihood of crystallization and an online server (SERp) from UCLA can identify 
good targets for mutagenesis (95, 97). For RioK3, SERp identified two locations, 
each a series of three residues that are most likely to improve crystallization.  
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Residues 222-224 and 276-278 had the sequences Glu-Lys-Lys (EKK) and Glu-Lys-
Glu (EKE), respectively. To make these mutations, Qiagen’s QuikchangeTM Lightning 
kit was used with RioK3-Short as the template DNA.  For both locations, the mutants 
were first double mutated yielding constructs RioK3-KK223AA and RioK3-
KE277AA, and then the third mutation was introduced creating RioK3-EKK222AAA 
and RioK3-EKE276AAA. For all four mutated constructs, there was no difference in 
the expression and successful purification protocol from the original RioK3-Short 
fragment. All four mutants were concentrated with no issue and subjected to 
crystallization screening via the PhoenixTM.  There were no crystals observed for 
RioK3-KE277AA and RioK3-EKE276AAA. Crystals were observed for RioK3-
KK223AA and RioK3-EKK222AAA in the same condition and same crystal form as 
the original RioK3-Short.  The inability to acquire a new crystal form from SER was 
disappointing and suggested an entirely new direction had to be taken to acquire a 
new crystal form for RioK3. 
7.5: Limited Proteolysis  
RioK3-Short, RioK3-S199A-Short, and all the surface entropy mutants were 
unsuccessful.  The optimization methods described above exhausted crystallization 
trials for the 193-519 constructs.  Focus shifted to determine a new RioK3 fragment 
that was both soluble and purifiable.  The RioK3 full-length construct was expressed 
with a histidine tag in E.coli overnight and purified by affinity chromatography.  
Originally, the RioK3 full-length construct was insoluble. However, lessons learned 
from RioK3-Short (addition of ATP and MgCl2) yielded small amounts of near pure 
soluble protein (~1 mg/L culture).  The quantity of RioK3 full-length was not suitable 
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for crystallization trials, but fitting for limited proteolysis using thermolysin, trypsin, 
and elastase.  The goal of the assay was to determine a stable construct that could be 
used for further crystallization trials.  The time based incubation assay was designed 
to identify a gel band that was consistent over more than one time point and seen in 
more than one protease. For trypsin and thermolysin, 50 µL of Riok3 full-length 
concentrated to 1 mg/mL was mixed with 9 µL of enzyme buffer containing 100 mM 
Tris pH 8.0, 100 mM NaCl, 5 mM CaCl2 and 1 µL of protease.  For elastase, the 
enzyme buffer only contained 200 mM Tris pH 8.0 and was set up in the same 
volumes.  The reaction was incubated at both 37 °C and on the bench at ~25 °C, with 
15 µL samples taken at 5, 10, 30, and 120 minutes. The proteolysis reaction was 
stopped through denaturation by the addition of gel loading buffer containing SDS 
and heated to 95 °C.  SDS-PAGE was used to analyze the samples (Fig 7.5A, B). 
Lane 3 from the elastase gel in Figure 7.5A shows a slice cut from the gel, 
highlighted by an arrow. This slice was sent to Dr. Yan Wang for complete in-gel 
tryptic digest and peptide determination via LC MS/MS. Dr. Wang was able to 
identify coverage from the gel band for residues 248-452 with 67% sequence 
coverage over that range. This result suggested a new design for the short constructs 
with deletions from both the N-terminus and the C-terminus.  When combined with 
additional information from previously reported Rio1 archaeal structure and PSI-
PRED secondary structure prediction tool, three new constructs (248-519, 248-474, 





GGTGGGTC for 248-519, 5'-GAGAACCTGTACTTCCAGGGAATGTTGGAGAC 
AATCACTGGC-3' and 5'-GGGGACCACTTTGTACAAGAAAGCTGGGTTATCA 
TGTGATGTTTAAGCCTGAAACAGC-3' for 248-474, and 5'-GAGAACCTGTACT 
TCCAGGGAATGGATTTAAAACTATCAAAC-3' and 5'-GGGGACCACTTTGTA 
CAAGAAAGCTGGGTTATCATGTGATGTTTAAGCCTGAAACAGC-3' for 193-
474 utilizing previously described Invitrogen’s GatewayTM cloning (Fig 7.5C) (35, 98, 
99). These three constructs were subjected to expression and solubility testing. 
RioK3-248-474 and RioK3-248-519 were completely insoluble and could be 
collected in the cell pellet. RioK3-193-474 expressed and was partially soluble for the 
first step of purification. However, upon elution from the affinity column, the soluble 
protein immediately precipitated. The buffers for RioK3-193-474 were modified to 
prevent precipitation by varying the components (200 mM and 500 mM NaCl, ±1 
mM ATP,  ±10% glycerol). Buffer variations were unable to overcome RioK3-193-
474’s insolubility.   
7.6: RioK3 Conclusions 
My goal of solving the structure of RioK3 was an exhaustive lesson on the 
difficulties of both crystallography and protein purification.  The only way to learn 
the “tricks” of crystallography, whether it be surface entropy mutations or an outside 
the box “X” method of optimization, is to gain experience through a challenging 
project.  Ideally, one of the methods employed to improve diffraction works. 
However, this was not the case for RioK3.  I confidently leave this project knowing 
the next person can successfully take lessons learned from my trials and apply that 
knowledge to acquiring a structure.  I leave the RioK3 project with multiple soluble 
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constructs and a roadmap toward success based on the results from past experiments 
presented in this manuscript.  My successes with expression, purification and 
crystallization overshadow the lack of a “hero” crystal. The next researcher fortunate 
enough to take over this project will be one step away from success. Maybe that 
researcher will continue to eliminate possible paths as I have during my tenure, or 
maybe that researcher will choose correctly on their first try.  In any case, I believe 




Figure 7.1: “X” Method 
A) Cartoon representation of “X” method.  Protein is streaked into the formation of 
an “X” with pipette tip and then precipitant is added to the center of the “X” as 
shown. B) Image taken with digital camera of crystals growing in the metaphase 
region created by dilution between precipitant near the center and soluble Riok3-





Figure 7.2: Indexing of Riok3-Short 
A) Diffraction image from Riok3-Short crystal grown in minimal media showing the 
fitment of spots after refining in the primitive hexagonal point group. B) Choices of 
point groups determined form Riok3-Short diffraction image in (A). The highest 
symmetry with the lowest score (primitive hexagonal colored green) was chosen and 
confirmed during scaling, using Scalepack. DENZO, a program within the HKL2000 






Table 7.2: Matthews Coefficient Logfile 
Matthews Coefficient logfile showing the number of possible monomers in the 
asymmetric unit, based on MW 37,717 Da. Highlighted in yellow are the most likely 




Figure 7.3: RioK3-Short MW Determination and LC MS/MS 
A) Molecular weight determination of RioK3-Short. The expected MW for RioK3-
Short is 37,717 Da. B) Results from peptide identification via tryptic digestion 
followed by LC MS/MS. Red residues indicate identified residues with a box around 
serine 199, the only phosphorylated residue identified.  Dr. Yan Wang at the 
University of Maryland Proteomics Center performed all mass spectrometry for 




Figure 7.4: RioK3-S199A-Short Crystals 
A) Digital image of RioK3-S199A-Short crystals grown in the Wizard II screen 
position E3, containing 24% PEG-8000, 0.1 M Tris pH 8.0, 0.2 M MgCl2. B) The 
largest crystals grown for RioK3. This image was photographed from an optimization 




Figure 7.5: Limited Proteolysis of Riok3 Full-length 
SDS-PAGE of RioK3 full-length subjected to limited proteolysis with elastase, 
shown in (A), trypsin or thermolysin, both shown in (B). Horizontal arrows point to 
band of interest and the red diagonal arrow in (A) points to gel slice removed for 
mass spectrometry. C) Representation of fragments created from limited proteolysis 
assay (green = 248-519, purple = 248-474, blue = 194-474, black = original Riok3-
Short 193-519). MVNSGM cuts off the “extended” archaeal Rio1 domain, supported 
by the MS/MS results (35). RELF-NIT is homologous to the last archaeal Rio1 alpha 
helix I (35).  “????” represent unfolded region predicted from PSI-PRED (99). 
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Chapter 8: My Role in Ubiquitin  
8.1 Overview and Thanks 
I would like to thank Dr. David Fushman at the University of Maryland, a 
member of the Center for Biomolecular Structure and Organization (CBSO), for the 
opportunity to learn and teach while working on his Ubiquitin projects.  My role in 
Ubiquitin has been two fold. First and foremost, my responsibility was to provide 
advice and consultation to members of his laboratory who had an interest in learning 
the basics of crystallography. Shirley Lee, current graduate student at the University 
of Michigan was the primary contact for Dr. Fushman. My second purpose for the 
multiple Ubiquitin projects was to provide expertise and resources not available to 
Dr. Fushman.  This goal was met by providing beamtime during synchrotron trips and 
access to instrumentation in the Dr. LaRonde-LeBlanc lab, along with guidance on all 
shared instrumentation.  It should be noted that my role in Ubiquitin was strictly 
crystallographic in nature, meaning I only provided suggestions and guidance in 
crystal growth/optimization, crystal harvesting, data collection, and structure solution. 
I was not responsible for project direction or the selection of crystallographic targets. 
Many of the targets chosen by Dr. Fushman were site-directed mutants of human 
Ubiquitin, designed to look at confirmation changes introduced by the selected 
mutations.  Three of these mutants provided crystals that diffracted to 2.0 Å or better. 
In chronological order, Ubiquitin leucine 69 to serine (L69S), isoleucine 13 to serine 
(I13S), and double mutant lysine 63 to aspartatic acid with glutamatic acid 64 to 
glycine (KE63DG) were all selected for x-ray structure determination. Near the end 
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of my tenure at the University of Maryland, I also helped with the structure 
determination of lysine 48-linked di-ubiquitin in complex with E2-25K, the protein 
known to be responsible for creating chains of ubiquitin through a covalent bond 
between lysine 48 and glycine 76 (100). The following is a description of results from 
my time spent with Dr. Fushman and his laboratory members.  
8.2: Methods for Structure Determination of Ubiquitin Mutant I13S 
Initial crystallization was done via sparse matrix screening (Wizard I & II & 
IIITM, NatrixTM, PEGTM Suite, CryoTM Suite, IndexTM) using Art Robbins PhoenixTM 
high-throughput robot.   The Phoenix utilizes the sitting drop method for screening 
for crystallization conditions. Ubiquitin I13S mutant crystals grew in 5-7 days.  
Optimization of crystals screened for diffraction were done via hanging drop method 
using a 24-well tray purchased from Qiagen. Crystallization conditions for Ubiquitin 
I13S mutant include 0.3M Ammonium Iodide, 26% PEG 3350, 100mM Hepes pH 
6.8, and 20% glycerol. Crystals were screened for diffraction and cryo conditions at 
the home souce (Microstar H2 generator with Proteum Pt135 CCD detector) at 100 K.  
Diffraction data sets were collected via Advanced Photon Source (APS) located at 
Argonne National Laboratory NECAT Beamline 24IID.  Ubiquitin crystal datasets 
were collected at a wavelength set at 1.00931 Å.  All data collected was integrated 
and scaled using HKL2000 (Table 8.1) (56).  The human Ubiquitin monomer (PDB: 
1ubq) was used as the search model for molecular replacement using Phaser within 
CCP4, for the structure solution of Ubiquitin I13S mutant (66, 70, 101). Refinement 
of the model was done primarily using Refmac5 within CCP4 and model building 
was done using COOT (64-66). The final solution intended for submission was 
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refined with PHENIX (72). I13S crystallized with four molecules in the asymmetric 
unit in space group P21. Figure 8.1 shows an overall cartoon view of the asymmetric 
unit. Statistics for I13S data collection and refinement are shown in Table 8.2. 
8.3: Ubiquitin Mutants L69S and KE63DG 
Crystals were obtained for L69S and KE63DG in the same manner as I13S 
(screening then optimization) and data was collected at both the home source and 
synchrotron. Unfortunately, both L69S and KE63DG were not solved due to 
problems with data quality. Specifically, both crystal forms used for data collection 
suffered from pseudosymmetry-related twinning that could not be resolved. 
Pseudosymmetry confuses space group selection due to non-crystallographic 
symmetry being close to crystallographic symmetry. This results in two or more 
possible spacegroups contained within the crystals. In this case, we were unable to 
successfully de-twin the data and molecular replacement could not effectively place 
molecules to provide accurate phases. This resulted in poor electron density and 
incorrect solutions.   
The first approach to resolving pseudosymmetry is going back to the original 
data to determine if there is a possibility that this space group confusion is caused by 
overlapping crystals, otherwise known as non-merohedral twins (common in plate 
crystals), thus giving two distinct overlaid diffraction patterns. After taking a closer 
look at diffraction patterns and scaling statistics, multiple crystals did not appear to be 
the cause of twinning.  The presence of a single lattice in the diffraction pattern and 
confusion between symmetry suggested pseudo-merohedral twinning. Pseudo-
merohedral twinning is the presence of multiple lattices of differing symmetries 
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directly overlaid on top of each other giving the appearance of a single crystal lattice. 
The next approach in this type of twinning was to re-index the collected data into 
lower symmetry, in this case primitive monoclinic (P2) instead of primitive 
orthorhombic (P222). Initially, the most likely space group determined for both L69S 
and KE63DG was P212121 (orthorhombic), which can be confused with P21 
(monoclinic) in a case of pseudosymmetry. Ideally, the elimination of symmetry not 
actually present should result in a usable dataset. This was not the case for the 
Ubiquitin mutants evident by the continued failure of molecular replacement. This 
suggested a more severe partial twinning that would require separation of the twinned 
data using a partial twin law. I was never successful in finding an appropriate method 
for solving these mutant structures.  In hindsight, work should have focused on the 
growth of many crystals and required full-time dedication to optimization of these 
twinned Ubiquitin crystals. 
8.4: E2-25K in Complex with Di-ubiquitin 
Near the end of my time spent with Shirley Lee, she grasped many of my 
teachings and was fully capable of making decisions and providing assistance to other 
members of Dr. Fushman’s laboratory. Ms. Lee provided her knowledge to help Dr. 
Rajesh Singh, postdoctoral reseacher in Dr. Fushman’s lab, prepare E2-25K and 
lysine 48 linked di-Ubiquitin protein complex and set up screening trays using the 
PhoenixTM liquid handler. Shortly after setting up the initial screening, Ms. Lee left 
the University of Maryland and beginning graduate school at the University of 
Michigan. I picked up where Ms. Lee left off and began work with Dr. Singh. The 
results from the screen were very encouraging with over 50 possible targets for 
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optimization. There were two distinct crystals forms, clean plates and circular “blob” 
crystals (Fig 8.2A, B).  I utilized the home diffraction source to collect a data set from 
both plate crystals and a “blob” crystal and confirmed the presence of the complex 
only in the “blob” form via a low-resolution (3.0 Å) structure solved by molecular 
replacement (72). This structure in P212121, solved with E2-25K and one monomer of 
Ubiquitin in the asymmetric unit. Crystallographic symmetry was present between the 
two monomers of linked Ubiquitin, resulting in the single monomer of Ubiquitin. 
There was no discernible electron density to model residues 73-76 between the 
Ubiquitin monomer and its symmetry related mate, and the covalent linkage between 
lysine 48 and glycine 76.  This could have been due to low-resolution diffraction, the 
crystallographic axis between the two monomers, or flexibility in the short 
polypeptide connecting the Ubiquitin monomers. The synchrotron was needed to 
collect higher resolution data. Crystals harvested from Qiagen’s CryosTM Suite 
containing 10.2% PEG-20000, 0.085 M MES pH 6.5 and 15% glycerol, diffracted to 
2.3Å at the NECAT beamline (Table 8.3). Molecular replacement was performed 
with Phaser within PHENIX, using a previously solved crystal structure of E2-25K 
and ubiquitin complex (PDB: 3K9P) (70, 72, 102). In space group P21, there are two 
monomers of E2-25K and two monomers of Ubiquitin (Fig. 8.3A). Residues 74-76, 
including the covalent linkage between lysine 48 and glycine 76, still could not be 
modeled due to poor electron density insufficient for accurate placement of those 
residues (Fig 8.3B). This suggests high conformational flexibility for these residues.  
Statistics for E2-25K and Ubiquitin complex are shown in Table 8.2. 
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8.5: Ubiquitin Conclusions 
Again, it has been an incredible opportunity to provide assistance to Ms. Lee, Dr. 
Singh, and Dr. Fushman.  Ubiquitin has truly been a lesson in both the successes and 








Figure 8.1: Ubiquitin I13S Overall View 
Cartoon Representation of the four Ubiquitin monomers (colored cyan, green, yellow, 
and magenta) in the asymmetric unit. Serine 13 is mutated from isoleucine and shown 















Figure 8.2: Possible Crystals Containing  E2-25K and Di-Ubiquitin Complex 
A) Digital image of one of many conditions that grew “blob” like crystal form. This 
crystal form was confirmed to contain E2-25K and di-Ubiquitin complex. B) Digital 
image of plate like crystals that also grew in many conditions (>30). This crystal form 
was later confirmed at the synchrotron to only contain Ubiquitin and not the E2-25K 







Figure 8.3: E2-25k and Di-Ubiquitin Complex 
A) Cartoon representation of the contents of the E2-25K and di-Ubiquitin complex 
asymmetric unit, which includes two molecules of E2-25K (magenta) and two 
molecules of Ubiquitin (green). B) Electron density 2Fo–Fc map contoured at 1σ, 
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showing the gap in electron density between the last built residue (leucine 73) and the 
expected covalent bond with lysine 48. 
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Chapter 9: Crystal Structure of Iodotyrosine Deiodinase, a Novel Flavoprotein 
Responsible for Iodide Salvage in Thyroid Glands 
9:1: Overview 
Chapter 9 includes portions of the work published with Dr. Patrick 
McTamney, Jennifer Adler, and Dr. Steven Rokita.  As first author on the article, and 
author of this dissertation manuscript, it is my commitment to discuss my 
responsibilities for the project and those responsibilities for which I was not the 
primary scientist.  This chapter will include modified text from the article including 
crystallographic methods (crystal screening, data collection, structure determination 
and refinement). Included, and not present in the published article, are 
crystallographic tables (Tables 9.1, 9.2, 9.3-9.5) representing the original data used to 
solve the protein structures. Results and Discussion has been limited here, the full 
article can be found through the Journal of Biological Chemistry (103). 
Dr. Patrick McTamney was responsible for all expression and purification of 
iodotyrosine deiodinase (IYD) protein. His work to achieve a soluble construct was 
exemplary and not described in this dissertation manuscript. The full experimental 
procedure for expression/purification work can be found through the University of 
Maryland library system in Dr. Patrick McTamney’s recently published dissertation 
(2009, http://hdl.handle.net/1903/9848). 
Jennifer Adler contributed to growing crystals and provided an excellent 
figure depicting the alignment of secondary structure between IYD and family 
members.  This alignment figure is not included with from the following and can be 
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found online in the official published copy from the Journal of Biological Chemistry 
(104). 
As senior author and the principle investigator for this project, Dr. Steven 
Rokita provided expert discussion and background knowledge for the IYD project. 
Dr. Rokita wrote all active site mechanistic results and discussion. Also Dr. Rokita 
provided an in-depth introduction, which was essential in providing the basis for 
structural analysis and guidance throughout the article. 
Finally, I have to acknowledge my advisor Dr. Nicole LaRonde-LeBlanc. She 
drove the crystallization and structure determination part of this project to success and 
provided all the necessary resources, both in terms of expertise and instrumentation, 
to complete this work.  
9.2: Statement of Authorization 
This research was originally published in Journal of Biological Chemistry. 
Seth R. Thomas, Patrick M. McTamney, Jennifer M. Adler, Nicole LaRonde-
LeBlanc, Steven E. Rokita. Title Crystal Structure of Iodotyrosine Deiodinase, a 
Novel Flavoprotein Responsible for Iodide Salvage in Thyroid Glands. Journal of 
Biological Chemistry. 2009; 284(29):19659-67. © the American Society for 
Biochemistry and Molecular Biology. 
9.3: Introduction 
Iodotyrosine deiodinase (IYD) salvages iodide from mono-iodotyrosine (MIT) 
and di-iodotyrosine (DIT) (105, 106). MIT and DIT are by-products from the 
proteolysis of thyroglobulin, a large protein (>300kD) responsible for the 
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biosynthesis of thyroxine (105). IYD is responsible for salvaging the iodide from 
MIT and DIT before excretion via a dehalogenation reaction for the purpose of 
recycling the iodide back into thyroglobulin, and subsequently the biosynthesis of 
thyroxine in the thyroid.  If iodide is not recycled properly by IYD, then the 
acquisition of iodide from outside sources (diet) becomes the only pathway to gather 
iodide into the thyroid (107, 108). If for any reason the quantity of available iodide is 
insufficient for the biosynthesis of the essential thyroid hormones, then the 
unfortunate individual may suffer from hypothyroidism. Weight gain, fatigue, 
depression, weakness, constipation, and many other symptoms characterize 
hypothyroidism, resulting in a very serious condition (109). Currently, the most 
successful treatment for hypothyroidism is an oral supplement to replace insufficient 
levels of thyroxine (109). However, the treatment does not help everyone and more 
fundamental research needs to be performed to better understand the homeostasis of 
iodide in the human body. Presented in this chapter are three structures of IYD, one 
with IYD and cofactor flavin mononucleodite (FMN) and two structures solved in the 
presence of both cofactor and their substrate MIT or DIT, at 2.0 Å, 2.45 Å, and 2.6 Å, 
respectively. These structures provide an understanding for IYD mutations found in 
patients suffering from hypothyroidism. 
9.4: Experimental Procedures 
9.4A: Gene Construction of a Soluble and Affinity-tagged IYD 
Gene construction of the soluble fragment used for crystallography is 
attributed to the hard work of Dr. Patrick Mctamney and Dr. Steven Rokita. The full 
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description of cloning can be accessed in the experimental procedures section of 
Thomas et al. (103) and in Dr. Patrick McTamney’s dissertation (2009, 
http://hdl.handle.net/1902/9848). Briefly, the successful construct was truncated by 
33 amino acids on the N-terminus to remove the membrane anchor domain and 
included an uncleavable His6 tag on the C-terminus for purification. This truncation 
resulted in a soluble construct that met the purity and quantity requirements needed 
for crystallography. 
9.4B: Expression and Purification of IYD 
Dr. Patrick McTamney and Dr. Steven Rokita were responsible for the 
expression and purification of IYD. One of the major factors in determination of the 
feasibility of IYD structure determination was their ability to provide ample amount 
of pure protein for crystal screening and optimization. The full description of the 
expression of IYD in Sf9 cells and purification by affinity chromatography can be 
accessed in the experimental procedures section of Thomas et al. (103) and within Dr. 
Patrick McTamney’s dissertation (2009, http://hdl.handle.ne/1902/9848). 
9.4C: Crystallization 
Initial crystallization was explored with sparse matrix screening (WizardTM I, 
II, and III (Emerald Biosciences); PEGSuiteTM and CryoSuiteTM (Qiagen); and 
NatrixTM and IndexTM (Hampton Research)) using an Art Robbins PhoenixTM high 
throughput liquid handler. Ultimately IYD was crystallized at 20 °C in three different 
crystal forms by the hanging drop vapor diffusion method using two parts IYD (16 
mg/ml; 10 mM potassium phosphate, pH 7.4) to one part reservoir solution. IYD 
 
117 
crystals were obtained using a reservoir solution containing 20% (w/v) polyethylene 
glycol 3000, and 0.1 M sodium acetate, pH 4.5. IYD·MIT co-crystals were obtained 
by supplementing the enzyme solution with 2 mM MIT prior to addition of the 
reservoir solution containing 0.2 M magnesium chloride, 20% (w/v) polyethylene 
glycol 3350, 10 mM potassium phosphate, pH 7.4. IYD·DIT co-crystals were 
obtained by supplementing the enzyme solution with 2 mM DIT prior to addition of 
the reservoir solution containing 0.2 M ammonium acetate, 45% 2-methyl-2,4-
pentanediol, 0.1 M BisTris, pH 5.5. In each case, yellow crystals appeared within 24 
h. Crystals grew as connected clusters that required dehydration and micro-dissection 
to separate out single crystals. 
9.4D: Data Collection 
Initial crystals were screened for diffraction and cryo conditions using a 
Bruker Microstar H2 generator with Proteum Pt135 CCD detector at 100 K. 
Diffraction data sets were then collected at the Northeastern Collaborative Access 
Team Beamline 24-ID, Advanced Photon Source, Argonne National Laboratories. 
Diffraction data for IYD was collected at a wavelength of 1.653 Å for single 
anomalous diffraction phasing using sulfur atoms. In order to obtain the required 
redundancy and signal to noise ratio for the sulfur anomalous signal, data sets were 
collected using varying parameters including exposure time to minimize radiation 
damage. Diffraction data of co-crystals containing MIT and DIT alternatively were 




9.4E:  Sulfur Phasing and Refinement 
All nine sulfur positions within IYD were found using SHELX within 
HKL2MAP program suite (Table 9.1) (110-112). Heavy atom positions were refined, 
and initial phases were determined using the AutoSHARP program set (63). Initial 
model building was performed by WARP within AUTOSHARP (63). Because of the 
complexity of the monomeric fold, nearly half of the residues were not built and 
required manual building. Several rounds of model building and refinement were 
needed for IYD using Refmac5 with TLS refinement and COOT for molecular 
visualization and rebuilding (64-66). A monomer of IYD was used as a model for 
molecular replacement to solve the structure of the co-crystal containing MIT. One 
dimer of this co-crystal was used in turn as the model for molecular replacement to 
solve the co-crystal containing DIT. Molecular replacement was performed by 
PHASER within the CCP4 program suite (66, 70). These structures were also rebuilt 
and refined by iterations of Refmac5 and COOT (64). IYD·DIT was initially solved 
in space group P212121 and suffered from pseudosymmetry, evident after multiple 
rounds of refinement with high R-factors. Re-indexing IYD·DIT diffraction data into 
primitive monoclinic and subsequent determination of the structure in P21 removed 
the overestimated symmetry and allowed for proper refinement. Refinement statistics 
are provided in Table 9.2. Tables 9.3-9.5 show data collection log files for all three 




9.5A: Overall Structure of the Soluble Domain of IYD 
In the absence of substrate, IYD crystallized with one monomer per 
asymmetric unit. However, analysis of the crystal packing interactions revealed an 
extensive interface with a symmetry-related molecule (2490 Å2 per monomer) 
indicating that the enzyme forms a domain-swapped dimer as observed in related 
proteins within the same structural superfamily (113-116). The IYD·MIT complex 
crystallized with two monomers per asymmetric unit, and the IYD·DIT complex 
crystallized with eight monomers per asymmetric unit. All three structures were 
solved from distinct crystal forms (Table 9.2). Electron density for the first 34 amino 
acids of the truncated enzyme was not observed for any of the three crystals. These 
residues in the native protein likely provide a flexible linker between the soluble 
domain and the N-terminal anchor embedded in the membrane. 
As mentioned, IYD contains the characteristic α-β fold that is common to all 
proteins of the NADH oxidase/flavin reductase superfamily (Fig. 9.1, Supplementary 
Fig. S1). The closest structural neighbor to IYD as determined by DaliLite (117) is 
BluB (Protein Data Bank code 2ISK) (116) with an (RMSD) of 3.1 Å for 198 
structurally equivalent residues of 219 possible residues. Despite the structural 
similarities, their sequence identity is quite low (19%). The net catalytic turnover of 
BluB appears to be very different from IYD, and BluB has been recently identified as 
the source of the lower ligand (5,6-dimethylbenzimidazole) of vitamin B12 by 
sacrificing its bound FMN cofactor to oxidation (116). Still IYD and BluB form 
similar dimer interfaces at their core with criss-crossing helices and similar domain 
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swaps with their extended N- and C-terminal fingers (Supplementary Fig. S2). Upon 
binding substrate, MIT/DIT for IYD and molecular oxygen for BluB, the lid forms 
holding in the substrate near FMN. The differences between the IYD and BluB active 
site lid positioning may determine the specificity and explain the difference in 
function (Fig. 9.2).  Blub active site lid caves in much closer to the FMN molecule, 
which would not be enough room for MIT or DIT to fit in the active site. 
9.5B: Interface Structure of the Homodimer 
For IYD, N- and C-terminal extensions of each polypeptide wrap around the 
other. These extensions span distances of greater than 37 Å and comprise a minimum 
of 26 amino acids near the N-terminus and 18 amino acids at the C-terminus. Two 
equivalent active sites are located within the dimer interface, and each active site is 
comprised of residues from both subunits. Accordingly subunit association is 
essential for FMN binding and catalytic activity. Because the IYD structure was 
solved as a monomer per asymmetric unit, its dimer was generated by 
crystallographic symmetry, and consequently no differences between the two 
monomers were observed. Differences observed between the monomeric units of 
IYD·MIT and IYD·DIT were minimal as evident from their root RMSD values of 
0.196 Å and 0.254 Å, respectively. 
9.5C: Substrate-induced Conformational Changes in the Active Site 
Two unstructured regions were identified within substrate-free IYD by the 
lack of electron density corresponding to residues 156–177 and 195–208. Even in the 
substrate-bound co-crystals, the regions containing residues 195–208 exhibit 
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relatively weak electron density compared with other regions of the molecule. Only 
portions of this region, some with higher than average B-factors, could be built for 
IYD bound to substrate. 
In contrast, residues 156–177 gain detectable structure based on the additional 
electron density observed for the co-crystals IYD·MIT and IYD·DIT. Substrate 
binding appears to induce the extension of one helix (αC) and the formation of 
another short helix (αD) in this region to cover the active site and protect substrate 
and flavin from solvent (Fig. 9.1B, D). This active site lid is stabilized in part by 
numerous interactions with the bound substrate that is in turn anchored by aromatic 
stacking with the isoalloxazine ring of FMN as well as by polar contacts with FMN 
and Ala-126 (Fig. 9.1E). Eight residues of the lid assemble within 4 Å of the 
substrate, and three of these form polar contacts (Glu-153, Tyr-157, and Lys-178). 
An analysis of sequence conservation onto the surface of IYD indicates a high 
level of conservation on one face of the molecule, but not the other. I have designated 
those as front and back faces for analysis. Figure 9.3A shows the conserved face 
(front) of the protein along with solvent accessible FMN.  As expected, there is 
significant residue conservation near the active site, and this conservation extends 
across this face. It is assumed that IYD requires interaction with a currently unknown 
reductase that binds and reduces the FMN. Therefore, the remaining conservation on 
the front face may be required for interaction with the reductase. The reductase would 
presumably bind to IYD and FMN when ligand is not present. Figure 9.3B displays 
the conserved surface when MIT is bound and the helical flap encloses the active site.  
The disappearance of the majority of the conserved surface supports the idea that the 
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conserved surface would only be required and open for binding when the substrate is 
absent. 
Electrostatic comparisons between IYD·Holo and ligand bound IYD·MIT 
show distinct structural changes, both in shape and electrostatic charge density on the 
front face of the protein in response to substrate binding (Fig. 9.1C, D).  It is clear 
that upon binding ligand the protein becomes more structured around the active site 
and the face of the protein becomes more defined with hydrophobic residues near the 
center and postively charged residues around the edges. This analysis also highlights 
that there is ample solvent accessibility to the FMN in the IYD·Holo to allow for 
substrate binding and interaction with a reductase. 
Both MIT and DIT are stabilized in the active site by electrostatic interactions, 
expected by the conserved positively charged arginine residues near the phosphate 
tail of FMN and the negatively charged area surrounding the amino group of the 
substrate (Fig. 9.4A). The active site lid forms locking in the substrate near the FMN 
cofactor and provides just enough space for the specific substrate to stack on top of 
the FMN molecule.  There is a slight conformational change of three nearby residues 
(Leu-169, Thr-174 and Leu-172) to allow enough room for DIT to fit into the active 
site (Fig. 9.4B).  
9.6: Structural Basis for Deficiency of IYD in Humans 
Moreno et al. discovered four mutations within the IYD gene from patients 
suffering from hypothyroidism (106). All mutations discovered are conserved in the 
mouse IYD gene, along with over 90% sequence identity between mouse and human 
homologs. This sequence conservation between human IYD and mouse IYD allows 
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for the acceptable explanation of the phenotypes expressed by the human mutations 
using the mouse IYD crystal structures. Mutations discovered at Arg101 to Trp 
(mouse: Arg97) and Phe105 and Ile106 to Leu (mouse: Phe101-Ile102) were 
observed in patients, and shown to completely abolish deiodinase activity (106).  
Arg97 is located at the rear of the active site, forming hydrogen bond to the phosphate 
group on the FMN cofactor (Fig. 9.5). Mutation of Arg97 to tryptophan would leave 
no room for FMN to bind correctly, resulting in the abolished activity. Phe101-Ile102 
are also located near the active site (Fig. 9.5).  Neighboring residue Arg100 extends 
and interacts with FMN intimately, with interactions to the 2’-ribityl hydroxyl group, 
N-1 and O-2. Mutations of Phe101-Ile102 to leucines would change the local 
structure of the loop and eliminate Arg100 interaction with FMN (Fig. 9.5).  The 
fourth mutation, Ile116 (mouse: Ile112) to Thr was found in patients but still 
exhibited some deiodinase activity. Ile116 is not located near the active site but is 
buried within the protein in a hydrophobic core, clear from any interactions of the 
active site (Fig 9.5).  Introducing threonine into the hydrophobic environment could 
create instability in the protein and could explain the decreased activity, albeit less 
severe.  
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Table 9.1: ShelX Results from HKL2MAP Program Suite.   
The nine sulfur atoms are identified as shown above the line in the ShelXE results 
logfile, with the strength of anomalous signal present shown in the ShelXC results 





Table 9.2: Data Collection and Refinement Statistics   
















Figure 9.1: IYD structure 
A) An overall view of the native homodimer of IYD crystallized in the absence of 
substrate. Each monomer is distinguished by color. Disordered regions consisting of 
residues 156–177 and 195–208 connect to the structure as indicated by ∗ and , 
respectively. B) Native homodimer of IYD crystallized in the presence of its 
substrate, MIT. Only the structure induced upon substrate binding is highlighted in 
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the colors of the monomers shown in (A). The surface properties of IYD (C) and its 
complex with monoiodotyrosine (D) were calculated using vacuum electrostatics in 
PyMOL (75). Blue indicates positive charge, and red indicates negative charge. E) 
Ionic interactions and hydrogen bonding stabilize the FMN·monoiodotyrosine 
complex formed by IYD. F) The interaction between FMN and MIT in the active site 
of IYD. An Fo − Fc electron density map calculated after refinement in the absence of 






Figure 9.2: Structural Overlay of IYD and BluB  
Structural differences between IYD·MIT (gray) and BluB (blue) are highlighted using 
an overlaid stereoimage. Structural changes near the active site are depicted with the 





Figure 9.3: IYD Sequence Conservation 
A) and B) shows front views of sequence conservation modeled onto the surface of 
IYD·Holo and IYD·MIT, respectively. Red=sequence identity. Green=strongly 
similar. Blue=weakly similar. Gray=no similarity White=FMN surface. C) and D) are 
rotated 180˚ around the x-axis in respect to (A) and (B).  ClustalW used for alignment 
from the following: M. musculus (mouse), X. laevis (frog), D. rerio (zebra fish), N. 







Figure 9.4: IYD Active Site Electrostatics and MIT/DIT Alignment 
A) The surface characteristics of the active site of IYD for the IYD·MIT co-crystal 
crystal calculated using vacuum electrostatics in PyMOL (47). Blue indicates positive 
charge, and red indicates negative charge. B) Alignment of active site structures of 
IYD bound with MIT (orange) and DIT (cyan) illustrates the minor conformational 






Figure 9.5: Mapping Human Mutations onto the Structure of IYD  
Native residues of IYD (M. musculus) highlighted in red correspond to sites 
associated with human mutations identified clinically to cause hypothyroidism (106). 
Other color coding is consistent with the previous illustrations (see legends) and 
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